



# RESI BOSTON JUNE 2025

June 16: Westin Copley Place, Boston | June 17-18 & 23: Virtual Partnering



**PRESENTED BY**



**LIFE SCIENCE  
NATION**

Connecting Products, Services & Capital

**ONSITE GUIDE**

Capital investors, licensing partners, fundraising CEOs, and service providers **Make a Compelling Connection**

## TITLE SPONSORS



RESIConference.com | Westin Copley Place  
#RESI #RESIBOSTONJUNE



# RESI

## 2025-26 CONFERENCE SERIES



### RESI BOSTON 2025

SEPT 17: THE WESTIN COPLEY PLACE, BOSTON  
SEPT 18-19: VIRTUAL PARTNERING



### RESI LONDON 2025

DEC 4: 11 CAVENDISH SQUARE, LONDON  
DEC 5-6: VIRTUAL PARTNERING



### RESI JPM 2026

JAN 12-13: SAN FRANCISCO MARRIOTT MARQUIS  
JAN 14, 19 & 20: VIRTUAL PARTNERING

Take **\$100** off with discount code **RESI100** for future RESIs.

For more information about our future events,

visit our website [RESIConference.com](https://RESIConference.com) or contact us at [RESI@lifesciencenation.com](mailto:RESI@lifesciencenation.com).

## CONTENT

# RESI BOSTON JUNE 2025

Welcome to RESI	1
Floor Plan	2
RESI Agenda	5
Sponsors & Exhibitors	10
Partnering Forum	18
Investor Panels	19
Innovator's Pitch Challenge	27
Entrepreneur's Workshops	43

# WELCOME TO RESI



## Welcome to RESI Boston – Redefining Every Stage of Investment

Thank you for joining us at RESI Boston, taking place at the Westin Copley Place. Life Science Nation (LSN) is proud to host this dynamic gathering of global investors, licensing partners, and innovators representing every stage of the healthcare investment landscape.

RESI Boston June offers a full day of programming designed to maximize exposure, engagement, and strategic opportunity. Each hour features investor panels, two concurrent tracks of the Innovator's Pitch Challenge (IPC), and interactive workshops. The IPC highlights a diverse group of presenting companies across biotech, medtech, diagnostics, and digital health, who pitch live to investor judges. Attendees can participate by voting online for their favorite companies, adding an interactive element to the experience. Be sure to explore the exhibit hall in the Essex Ballroom to connect with these innovators and learn more about their technologies.

Throughout the day, RESI attendees will also have the opportunity to engage with tech hubs and service providers that play an essential role in supporting company growth and fundraising efforts. These organizations are available through exhibits, panel discussions, and educational sessions. Our networking receptions provide additional space for fostering new relationships and expanding professional networks.

A key feature of the RESI Boston experience is the Global Family Office BioForum, which serves as a dedicated forum for investors to explore direct investments, syndication strategies, and capital allocation across healthcare sectors. This initiative includes a public Family Office Panel and an invitation-only luncheon for curated participants. Topics include sourcing innovation assets, selecting investment vehicles, and building strategic collaborations.

We are pleased to welcome this year's luncheon keynote speakers: Chris Garabedian, Founder & CEO, Xontogeny Portfolio Manager, Perceptive Xontogeny Venture Fund and Rick Berenson, Executive Committee Member, Mass Medical Angels (MA2).

We also extend our sincere thanks to our Title Sponsors, Biometas and Polsinelli, and supporting sponsors Tecan and Abiquifi. Their partnership is instrumental in creating the connections and collaborative environment that define RESI.

RESI's partnering platform continues to be the foundation of this conference, matching companies with capital, licensing, and channel partners through curated 1:1 meetings. In-person partnering takes place today, and continues virtually through Friday, June 6, extending the opportunity for meaningful dialogue with participants from around the world.

We look forward to a productive and impactful week of innovation and investment.

**Sougato Das**  
President and Chief Operating Officer  
Life Science Nation



# THE WESTIN COPLEY PLACE

## 3RD FLOOR

WiFi: RESI\_Conference  
PW: resi2025

**7:00 AM - 5:00 PM:** Partnering Meetings (Essex Ballroom & Staffordshire)

**7:00 AM - 8:00 AM:** Breakfast Buffet (Foyer)

**9:00 AM - 5:00 PM:** Investor Panels (St. George A&B)


**9:00 AM - 5:00 PM:** Innovator's Pitch Challenge Tracks 1&2 (Essex Northwest & Northeast)

**9:00 AM - 5:00 PM:** Workshops (St. George C)

**12:00 PM - 1:00 PM:** Global Family Office BioForum Luncheon (St. George D - Private luncheon by Invitation Only)

**12:00 PM - 1:00 PM:** Lunch (Foyer)

**5:00 PM - 7:00 PM:** Cocktail Reception (Foyer)



# EXHIBIT TABLES

Location: Foyer



Table #2



Table #3&4

BIG4BIO

Table #5



Table #6



Table #7



Table #8



Table #9



Table #10



Table #11



Table # 12



Table #13



Table #14



Table #15



Table #16



Table #17



Table #18



Table #19



Table #20



Table #21

## INNOVATOR'S PITCH CHALLENGE

Location: Essex Ballroom



Table #1



Table #2



Table #3



Table #4



Table #5



Table #6



Table #7



Table #8



Table #9



Table #10

# INNOVATOR'S PITCH CHALLENGE

Location: Essex Ballroom



Table #11



Table #12



Table #13



Table #14



Table #15



Table #16



Table #17



Table #18



Table #19



Table #20



Table #21



Table #22



Table #23



Table #24



Table #25



Table #26



Table #27



Table #28



Table #29



Table #30



Table #31



Table #32



Table #33



Table #34



Table #35



Table #36



Table #37



Table #38



Table #39



Table #40



Table #41



Table #42



Table #43



Table #44



Table #45



Table #46



Table #47



Table #48



Table #49



Table #50



Table #51



Table #52




Table #53

# AGENDA




7:00 AM – 5:00 PM: Onsite Partnering (Essex Ballroom + Staffordshire)

7:00 AM – 8:00 AM: Breakfast Buffet (Foyer)

	Investor Panels (St. George A&B)	Innovator's Pitch Challenge		Investor Panel & Workshops (St. George C)
		Track 1 (Essex Northwest)	Track 2 (Essex Northeast)	
9:00 AM - 9:50 AM	<b>BEYOND BIG PHARMA PANEL</b> <i>Partnering Early to Foster Innovation</i>	<b>SESSION #1 MEDICAL DEVICES</b>	<b>SESSION #8 MEDICAL DEVICES &amp; DIGITAL HEALTH</b>	 <b>LIFE SCIENCE NATION</b> <small>Connecting Products, Services &amp; Capital</small> <b>IT ALL STARTS WITH YOUR STORY</b>
10:00 AM - 10:50 AM	<b>AGING AND LONGEVITY PANEL</b> <i>Investing for Healthier Lifespans</i>	<b>SESSION #2 R&amp;D / LIFE SCIENCE TOOLS</b>	<b>SESSION #9 THERAPEUTICS</b>	<b>TALES FROM THE ROAD</b> <i>Biotech and MedTech Innovators on their Fundraising Journey</i>
11:00 AM - 11:50 AM	<b>HEALTH SYSTEM PARTNERS PANEL</b> <i>Novel Partnering Approaches to Improve Quality of Care</i>	<b>SESSION #3 THERAPEUTICS</b>	<b>SESSION #10 MEDICAL DEVICES &amp; DIAGNOSTICS</b>	<b>CROSS-BORDER VENTURE BUILDING STRATEGIES</b> <i>How Service-for-Equity &amp; Global Structuring Can Transform Early-Stage Therapeutics Partnerships</i>

12:00 - 1:00 PM: Lunch Break (Foyer)

12:00 - 1:00 PM: Global Family Office BioForum Luncheon  
(St. George D - Private luncheon by Invitation Only)

1:00 PM - 1:50 PM	<b>AI IN HEALTHCARE PANEL</b> <i>Investing in the Intersection of Life Sciences and Technology</i>	<b>SESSION #4 THERAPEUTICS</b>	<b>SESSION #11 MEDICAL DEVICES</b>	<b>FAMILY OFFICES PANEL PANEL</b> <i>Perspectives on Early-Stage Investments</i>
2:00 PM - 2:50 PM	<b>ALTERNATIVE FUNDING SOURCES</b> <i>Funding Opportunities for Early-Stage Companies</i>	<b>SESSION #5 MEDICAL DEVICES</b>	<b>SESSION #12 THERAPEUTICS</b>	 <b>POLSINELLI</b> <b>TERM SHEETS</b>
3:00 PM - 3:50 PM	<b>CNS DISEASES PANEL</b> <i>Latest Innovations and Investment Trends</i>	<b>SESSION #6 DIAGNOSTICS</b>	<b>SESSION #13 THERAPEUTICS</b>	 <b>LIFE SCIENCE NATION</b> <small>Connecting Products, Services &amp; Capital</small> <b>GLOBAL PARTNERING CAMPAIGN INVESTOR LANDSCAPE, GTL AND CRM/GPC</b>
4:00 PM - 4:50 PM	<b>MEDICAL DEVICES PANEL</b> <i>Latest Trends in Medtech Investments</i>	<b>SESSION #7 THERAPEUTICS</b>	<b>SESSION #14 THERAPEUTICS</b>	 <b>VENTURE VALUATION</b> <small>GLOBAL VALUATION SERVICES</small> <b>COMPANY VALUATION FOR FUNDRAISING</b>

5:00 - 7:00 PM: Cocktail Reception - IPC Winners Announced (Foyer)

# Global Family Office BioForum Luncheon

12PM - 1PM | Westin Copley Place - St. George D (3rd Floor)

(Private luncheon by Invitation Only)

Life Science Nation (LSN) is pleased to announce the formal program for the Global Family Office BioForum (GFOB) and invites qualified family office investors to participate in this exclusive gathering.

Held during the Redefining Every-Stage Investments (RESI) Conference on Monday, June 16, at the Westin Copley Place in Boston, GFOB provides a private, curated environment for family offices to:

- Exchange strategies across asset classes and investment themes
- Share deal flow insights and emerging biotech opportunities
- Explore co-investment partnerships in early-stage therapeutics and healthcare innovation


## Two Keynotes. Two Models. One Mission: Smarter Access to Biotech.

This year's GFOB Luncheon features two complementary keynote speakers who will share actionable strategies for how family offices can participate in biotech investing without building internal venture teams or becoming scientific experts.



**Chris Garabedian**

Founder & CEO, Xontogeny I  
Portfolio Manager, Perceptive  
Xontogeny Venture Fund



**Rick Berenson**

Executive Committee Member,  
Mass Medical Angels (MA2)

## Agenda Highlights:

### 1. Welcome/Opening Remarks

- Dennis Ford, Founder & CEO, Life Science Nation

### 2. Opening Discussion

- Chris Garabedian, Founder & CEO, Xontogeny I Portfolio Manager, Perceptive Xontogeny Venture Fund
- Rick Berenson, Executive Committee Member, Mass Medical Angels (MA2)

### 3. Private Networking Luncheon

In addition to the private luncheon and networking session, GFOB will feature a Family Office Investors Panel open to all RESI attendees. The panel will spotlight perspectives from seasoned family office investors who are actively deploying capital in the life sciences and healthcare sectors.

# RESI BOSTON 2025

JUNE 16, 2025

THE WESTIN COPLEY PLACE  
BOSTON, MA, U.S.A.

[www.biometasgroup.com](http://www.biometasgroup.com)

**Choose BioMetas as your partner  
for your next breakthrough**

**Made Assay Easy**



**WE WANT TO SERVE YOU**

**BioMeta**   
Advancing your discovery



# What a law firm *should be.*<sup>TM</sup>

Polsinelli's nationally recognized multidisciplinary team provides life sciences and health care clients with a full-service approach through every stage of the corporate lifecycle, from start-up to growth to liquidity. We counsel clients on entity formation, pre-seed/seed/venture stage financings, patent prosecution and strategy (including Freedom to Operate opinions), in-licensing and out-licensing, FDA compliance, health care reimbursement and litigation (including Hatch-Waxman and ITC), collaborations, mergers and acquisitions and public offerings/SEC compliance. We have deep industry experience in all of the life science verticals — including biotech, medical devices, pharmaceuticals, digital health, food and agriculture — as well as health care — including hospitals and health systems, pharmacies, behavioral health, home health and hospice, infusion therapy, and long-term care/assisted living facilities.

We look forward to the opportunity to connect!

Am Law 100 firm | 1,200+ attorneys nationwide  
25+ offices from LA to NY | 170+ services/industries

[polsinelli.com](http://polsinelli.com) | The choice of a lawyer is an important decision that should not be based solely upon advertisements. © 2025. Polsinelli PC, Polsinelli LLP in California, Polsinelli PC (Inc) in Florida.

## CAPABILITIES

Business

Health Care

Intellectual Property

Litigation

Labor & Employment

Real Estate

Regulatory



**MEDMARC**<sup>®</sup>  
LIFE SCIENCES INSURANCE

# Insuring the Life Sciences Industry Since 1979

- Products Liability
- Clinical Trials Liability
- Manufacturers E&O

Phone: 888.633.6272 | Email: [MedTechLifeSci@medmarc.com](mailto:MedTechLifeSci@medmarc.com)  
4795 Meadow Wood Lane | Suite 335 West | Chantilly, VA 20151

**LEARN MORE**  
**[medmarc.com](http://medmarc.com)**

# SPONSORS & EXHIBITORS

## TITLE SPONSORS



## GOLD SPONSOR



## SILVER SPONSORS



## EXHIBITORS



# RESI CONFERENCE SERIES PRESENTED BY LIFE SCIENCE NATION

Life Science Nation (LSN) has built a global partnering ecosystem featuring healthcare startups and the capital investors, co-development, and licensing partners who seek them. LSN accelerates the fundraising journey by bridging the gap between early-stage entrepreneurs, capital investors, and licensing partners.

- LSN's GPC Platform and RESI Conference Series are invaluable resources for sourcing partners based on product, stage of development, and allocation requirements. These resources are curated regularly and allow for dynamic matching based on fit.
- This one-of-a-kind partnering ecosystem is unique because it is cross-domain, serving the silos of Drugs, Devices, Diagnostics, and Digital Health (the 4Ds).
- The LSN platform also includes relationships with the service providers, tech hubs, and government agencies that provide the international infrastructure that makes the early-stage life science industry run.
- LSN's partnering platform has three components:
  1. Early-Stage Capital and Licensing Partner data profiles integrated with Salesforce CRM
  2. RESI Partnering Events
  3. Entrepreneurial Education and Roadshow Preparation



**Table #3, 4**

Global Partnering Campaign (GPC), Fundraising & Licensing Partner Roadshow Management.

The GPC integrates LSN's Investor and Licensing Partner Database and the Salesforce CRM.


Subscribing companies receive a vetted Global Target List (GTL) of likely partners garnered through one-on-one interviews with the LSN research team, which can be organized into three tiers of Investor Priority:

- Tier 1: Partner is matched on a specific mandate.
- Tier 2: Partner is matched on an opportunistic mandate seeking compelling technology assets.
- Tier 3: Partner is matched as a potential fit based on past or recent actions. This is where the numbers game comes into play.

Information on these profiles is automatically updated daily, and user outreach and tasks can be tracked intuitively with CRM components, including the following:

- Status of Outreach (Lead, Reviewing Materials, Call/Meeting Scheduled, etc.)
- Materials Sent (Executive Summary, Pitch Deck, etc.)
- Notes (NDA status, DD, and data room)
- Reporting (investor/licensing pipeline)

Life Science Nation's (LSN) publications offer a current dialogue for early-stage (seed to series A), life science, fundraising companies to sharpen the skills needed to create a compelling fundraising campaign. These publications include education on how to increase fundraising and marketing efforts for their organization or affiliated startups, expert interviews, event announcements, and active investor mandates. Subscribe and stay up-to-date with meaningful insight into raising capital in the life science industry.



## SPONSORS & EXHIBITORS



**Table 2**

**BioMetas: Supporting the Next Generation of Therapeutic Startups**  
BioMetas is a trusted partner for early-stage biotech innovators, providing a comprehensive suite of preclinical research services. With expertise spanning in vitro biology, in vivo pharmacology, cancer biology, protein science, and immunology, BioMetas enables startups to progress their drug development programs efficiently. By streamlining the preclinical process and providing milestone-driven support, BioMetas helps biotech companies de-risk their assets and position them for successful global partnering opportunities.



**Table 15**

Polsinelli is an Am Law 100 firm with more than 1,000 attorneys in over 20 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients' expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on life sciences, health care, real estate, finance, technology, and private equity.



**Table 14**

Created in 1979 by the healthcare technology industry, Medmarc's mission is to be the superior provider of liability insurance protection and related risk management solutions to the medical technology industry. We support the research and development, manufacturing, and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our strategic alliance carriers in the U.S. and abroad, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – We Can Meet Your Changing Needs. Contact us to discuss the cost of insurance coverage and what coverages are needed for your business plan. (703) 652-1360



**Table #9**

The ABIQUIF-Pharma Chemicals Industry Association (Associação Brasileira da Indústria Farmoquímica) was founded in 1983 and early 2010 to more actively represent companies engaged in the production of pharmaceutical adjuvants, or non-active pharmaceutical ingredients, was renamed Abiquif – Industry Association Pharma Chemicals and Chemical Products. The inclusion of an additional 'i' in its name demonstrates more than 25 years of continuous work and the fruitful Abiquif in favor of a strong Brazilian pharmaceutical chemistry industry and also represents the beginning of a new era in support for various companies producing active pharmaceutical ingredients and no assets. In this new phase, Abiquifi renews its commitment to fight incessantly for an industry of pharmaceutical chemicals and pharmaceutical strong and modern in Brazil.



**Table #5**

Big4Bio is the leading aggregator service for the top life science regions in the world, providing developments of the "Big 4" focus areas: drugs, devices, diagnostics, and digital (also known as "the four D's"). Our free, daily emails give you easy-to-scan headlines and links to content gleaned from hundreds of credible bioscience news and industry sources. These email newsletters and additional channels provide complete, daily coverage of "Big 4" news, events, jobs, and more in these regions to the industry's top professionals and executives. Subscribe to the Big4Bio newsletters at [big4bio.com](http://big4bio.com)

## SPONSORS & EXHIBITORS

**MedTech  
Ahead**  
by **bene : studio**

**Table #17**

bene : studio is an end-to-end MedTech software design and development consultancy. With the majority of our experts located in our EU offices, we can dedicate well-educated engineers to your projects at competitive prices for the long term. Our group serves as your MedTech competency center for both team extension and managed projects, ranging from one dedicated expert to a team of 50. We cover UX, UI, and brand design, systems and architecture design, cybersecurity, data, AI, cloud, IoT, mobile, web, and backend engineering, all with a focus on FDA, MDR, and ISO compliance. For the past 10 years, we have been working on 100+ projects for US & EU clients, from stunning startup prototypes to large-scale systems for enterprises for companies including DynamiCare Health, GE Healthcare, Johns Hopkins University, Volkswagen Group, Cushman & Wakefield, Labworx, Coopah and many more.

 **TECAN.**

Tecan accelerates the development of energy-based medical devices, helping MedTech companies deliver innovations faster and with unmatched precision. Specializing in RF energy delivery and tissue therapeutics, our Boston-based team excels in applied research, utilizing industry-leading multiphysics simulation (Comsol) and customizable hardware/software platforms to assess multiple solution pathways simultaneously, reducing potentially years of prototyping into months. Tecan offers expanded capabilities from concept to commercialization. Through high-quality components, advanced development expertise, and scalable manufacturing we streamline the OEM process and support our customers in achieving their growth goals.

  
**one  
nucleus**

**Table #11**

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

  
**inertia**

**Table #8**

Inertia is a trusted partner for startups and innovators looking to bring bold product ideas to life. We support clients through every stage of hardware development—from concept to manufacturing—offering expertise in design, prototyping, engineering, and supply chain management. Beyond the creative spark, we handle the critical details that ensure success, like design for manufacturing and logistics. For us, innovation begins with a blank page and the belief that ‘nothingness’ can become something impactful. We’re inspired by the genius of our clients and team, driven to turn visionary ideas into real-world solutions. With curiosity as our compass and execution as our strength, Inertia is committed to building not just what’s new, but what’s needed—solutions that make life easier, better, and more joyful. With the right vision, we know we can go anywhere.

## SPONSORS & EXHIBITORS



**Table #12**

Eva Garland Consulting (EGC), helps innovators leverage non-dilutive funding to accelerate their technology development. By connecting our clients with the resources they need to support scientific advancement, EGC seeks to break down the barriers that exist in translating great scientific discoveries into solutions that can solve our society's most pressing problems. Our Ph.D. Grant Writing Specialists provide a highly efficient and effective approach to obtaining non-dilutive funding. EGC has helped its clients secure and manage over \$2 Billion in grants and contracts from government agencies including NIH, DARPA, BARDA, ARPA-H, DOD, CDMRP, MTEC, NSF, DOE, CIRM as well as from Private Foundations. EGC uniquely offers both Scientific and Accounting & Compliance expertise, thus supporting the full lifecycle of our clients' innovative research and development in the United States and worldwide.



**Table #7**

Boulder iQ is an expert contract consulting firm providing all the services a life science company needs to get its product to market. With expertise in regulatory, quality, product development, manufacturing and contract sterilization, our single-source solution speeds the product development and regulatory submissions process. Our mission is to expedite your pathway to market, with emphasis on the sterilization validation process. We offer comprehensive sterilization solutions, including Ethylene Oxide (EO) and Chlorine Dioxide (CD) sterilization, each with its unique benefits. Recognizing the need for a seamless transition from product development to market, we also offer assembly, packaging, and packaging validation to effectively bridge the gap and provide a holistic solution for our clients.



**Table #13**

Norgen Biotek has delivered high-quality, innovative research tools for over 25 years, supporting scientists worldwide in life sciences and molecular diagnostics. We specialize in sample collection, preservation, extraction, and detection products that drive high-throughput insights. Our technologies are trusted globally and cited in thousands of peer-reviewed publications. Norgen also offers expert Next Generation Sequencing services, with a focus on ultra-low concentration samples such as liquid biopsies and exosomes. With a commitment to excellence and collaboration, we aim to build long-lasting partnerships that empower discovery and improve lives. Learn more at [norgenbiotek.com](http://norgenbiotek.com).



**Table #18**

The HealthTech Hub Accelerator (HTH) identifies and supports high-potential Israeli health technology startups with strong U.S. market applicability. Funded by the U.S. Department of Health and Human Services, HTH helps de-risk each company's commercialization journey by providing direct access to top-tier experts, clinical and regulatory guidance, and go-to-market strategy. The program is led by the Advanced Regenerative Manufacturing Institute (ARMI)—a public-private partnership advancing the U.S. bioeconomy—in partnership with Mass General Brigham (MGB), the nation's largest hospital-based research enterprise. This U.S.-Israel partnership aims to accelerate transformative health innovations while strengthening bilateral health resilience and preparedness for future public health emergencies.

## SPONSORS & EXHIBITORS



**Table #16**

At BioLizard, we “think data” and “speak biology”, partnering with our clients to transform lives. Our expert team combines deep biological knowledge with proven expertise in AI and bioinformatics to tackle complex data challenges in human and animal health. Through our AI-native BioVerse platform, we accelerate biomarker discovery and enable actionable insights for modern drug development. With a global presence, we deliver tailored solutions in data management, bioinformatics, and AI to drive your data-driven strategy to biotech, pharma and diagnostic companies.



**Table #6**

- Haystack Science is a boutique consulting company focused on the evaluation of the translational potential of academic spinouts and preclinical companies.
- Our company can provide a systematic evaluation of a life-science startup, focusing on the key dimensions that drive success — quality of the science, unmet medical need, market opportunity, and competitive positioning.
- Haystack Science’s Company Assessment Profile provides an objective evaluation of a startup’s scientific and business potential and identifies gaps in company strategy for partnerships, investment, and long-term success.
- Our team has decades of experience working with hundreds of scientific founders from top academic centers, accelerators, venture funds and pharmaceutical companies.
- Haystack’s feedback is an essential business advantage for startup teams seeking to anticipate and address key questions when preparing for meetings with prospective investors.



**Table #10**

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

# SPONSORS & EXHIBITORS

## LONGEVITY GLOBAL

### Table #19

Longevity Global is a non-profit membership community dedicated to connecting entrepreneurs, investors, and scientists in the longevity space to create collaborations. We have chapters that host events around the world including in Boston, NYC, San Francisco, San Diego, Miami, Switzerland, and the UAE. Our largest event is the Longevity Summit held at the Buck Institute in the San Francisco Bay Area Dec 9-10th. You can sign up to be a member and register for events on our website <https://longevitygl.org/>. You might just meet your next co-founder, investor, hire, or friend at one of our events or online on our platform. Basic membership is free.

## FIRSTXFOUNDER

### Table #20

FirstXFounder was created by an entrepreneur for entrepreneurs. Mary Howard, the serial entrepreneur founder, was immeasurably aided by fellow founders in building her ventures. When she founded a corporate spin out that evolved into a venture backed company, her network of founders provided invaluable advice on the the strategy and execution of her start up: from sweat equity to space, from lawyers to funding, from corporate partnering to team building, Mary was helped by the recent experience, honest feedback and relevant perspective of early stage founders and advisers. When it was time to give back, the opportunity to run entrepreneurship programs for communities arose. In response, Mary started to build a team of experienced entrepreneurs and advisors to share their journey as coaches and mentors with competitively selected emerging ventures aided by a proven curriculum. In 2011, FirstXFounder began to deliver programs in NJ to life science emerging ventures. Invited to NYC in 2012, FirstXFounders now manages the top four programs in the Metro New York area: ELabNYC, Next Milestone, ABCT and WCBA. These programs are supported by the top US life sciences law firms, global pharma, the top regional life sciences accounting firm, the largest Metro New York hospital networks, experienced entrepreneurs, mentors, coaches and an Advisory board of entrepreneurs, hospitals and universities and investors coming together to build the Metro New York life sciences industry. If you would like to become part of this effort, we invite you to join us.

## CAMBRIDGE SCIENTIFIC CAMBRIDGE SCIENTIFIC LABS

### Table #21

Cambridge Scientific is a service company specializing in the sale of life science equipment. We offer equipment to the biotech and pharmaceutical industry including startups, universities, and hospitals, both nationally and internationally. Additionally, we operate our own Biotech Incubator called Cambridge Scientific Labs, where we provide cost-effective, fully furnished shared and private lab suites, complete with equipment provided by Cambridge Scientific.

# BIG4BIO

## Stay in the Know with BIG4BIO

TO GET YOUR INDUSTRY ESSENTIALS, **SUBSCRIBE TO OUR NEWSLETTER!**



**Big4Bio** is the premier aggregator of news and developments in the life sciences sector. Our name stands for the cornerstone “Big 4” in biosciences and health: drugs, devices, diagnostics, and digital (also known as the “four D’s”), and our free, daily emails give readers easy-to-scan headlines to

“Big 4” content gleaned from hundreds of credible news and industry sources. These newsletter reports are specialized into varying types from regional to occupational, providing industry stakeholders a full range of publications and options to get the information they need.

BIG4BIO  
BOSTON

BIG4BIO  
PHILADELPHIA

BIG4BIO  
SAN DIEGO

BIG4BIO  
SFBAY

BIG4BIO  
CAPITAL REGION

BIG4BIO  
LOS ANGELES

BIG4BIO  
NYC

BIG4BIO  
SEATTLE

SUBSCRIBE  
NOW!



WWW.BIG4BIO.COM

BIG4BIO  
DRUGS DEVICES DIAGNOSTICS DIGITAL

SAME NAME.  
NEW MEANING.  
NEW OPPORTUNITIES.

# PARTNERING FORUM

Location: Essex Ballroom & Staffordshire


**JUNE 16: IN-PERSON PARTNERING MEETINGS**  
**JUNE 17-18, 23: VIRTUAL PARTNERING MEETINGS**

Investor/In-licensor Type	Percentage
Venture Capital	27%
Angel & Family Office	19%
Big Pharma & Medtech	17%
Corporate VC	14%
Others	8%
Endowments/Foundations	6%
Government Organizations	9%

Startup Type	Percentage
Therapeutics	47%
Medical Device	32%
Diagnostics	16%
Digital Health	5%

## Who Meets with Whom at RESI Conferences

Service Provider Type	Percentage
Professional Services	39%
CRO/CMO	30%
Non-Profit	18%
Suppliers	8%
Others	5%



RESI provides a partnering forum for all stakeholders in the life science world to reach out to others and build the relationships that will carry new technologies towards commercialization.




# 9:00 AM - 4:50 PM | INVESTOR PANELS

Location: St. George A&B

## Moderator & Panelists


### 9:00 - 9:50 AM BEYOND BIG PHARMA PANEL

*Partnering Early to Foster Innovation*

**Marc Appel**, Managing Partner, Pacific Bridge NY   
**Salma Al-Zu'bi**, Investment Principal, Hikma Ventures  
**Dirk, Büscher**, Sr Director Grifols Innovation and New Technologies, Grifols  
**Chloé Lepretre**, Head of Global R&D Search and Evaluation, Servier  
**Nicolas Stalder**, Senior Investment Manager, Debiopharm Innovation Fund

### 10:00 - 10:50 AM AGING AND LONGEVITY PANEL

*Investing for Healthier Lifespans*

**Fiona Miller**, Managing Partner, quadraScope Venture Fund   
**Caleb Bell**, Advisor, Beyond Next Ventures  
**Bettina Ernst**, Director, BERNINA BioInvest  
**Ravi Mistry**, Venture Partner / Officer & Founding Team Member, 3i Partners  
**Jeremy Sohn**, Managing Partner, P74 Ventures  
**Alex Strasser**, Senior Associate, Apollo Health Ventures

### 11:00 - 11:50 AM HEALTH SYSTEM PARTNERS PANEL

*Novel Partnering Approaches to Improve Quality of Care*

**Jeff Stinson**, Director, HealthTech Arkansas   
**Eileen Flowers, PhD**, Director – Technology Development and Licensing, Memorial Sloan Kettering Cancer Center  
**Thomas Thornton**, Vice President, Innovation, Jefferson Ventures, Jefferson Health

### 1:00 - 1:50 PM AI IN HEALTHCARE PANEL

*Investing in the Intersection of Life Sciences and Technology*

**Joe Collura, MBA, MS BIOE**, Managing Partner, HelixPoint Capital   
**Leo Cui**, Partner, FoundersX  
**Ser-Chen Fu**, Partner, Pacific 8 Ventures  
**Adam Steinert**, CTO, Yahara Ventures  
**Bob Sweeney, DA, MS, MBA**, Principal & Co-Founder, Global Health Impact Fund  
**Sally Wang Liang**, Managing Partner, Xpanse Venture

### 2:00 - 2:50 PM ALTERNATIVE FUNDING SOURCES PANEL

*Funding Opportunities for Early-Stage Companies*

**John Pennett**, Angel Investor, Mid Atlantic Bio Angels   
**John Abeles**, General Partner, Northlea Partners  
**Nicolas Cindric**, Partner, Yahara Ventures  
**Marc Estigarribia**, Sr Partner/ Managing Director, MSQ Ventures  
**Prashant Shah**, Partner, O2h Ventures

### 3:00 - 3:50 PM CNS DISEASES PANEL

*Latest Innovations and Investment Trends*

**Zizi Imatorbhebhe**, CEO & Executive Partner, Bios Health Group   
**John Boyce**, Managing Director & Co-Founder, 28 Capital  
**Danny Carbonero**, Investor, PsyMed Ventures  
**Cheryl Kuai**, Managing Director, Sixty Degree Capital  
**Yogesh Dayma PhD**, Venture Partner, 1004 Venture Partners

### 4:00 - 4:50 PM MEDICAL DEVICES PANEL

*Latest Trends in Medtech Investments*

**Ralph Morales III**, Venture Partner / Executive-in-Residence, Aquillius Ventures   
**Ayah Hamdan**, Director & Ventures, Health, Plug and Play  
**John Tremblay**, Investor, Launchpad Venture Group  
**Mark Vreeke**, Co-Founder, Chemical Angel Network  
**Chris Yoo**, General Partner, Xcellerant Ventures  
**Don Zinn**, US Vice President US Business, Crossject

# 9:00 AM | BEYOND BIG PHARMA

## Partnering Early to Foster Innovation

Therapeutics companies often see Big Pharma as the ultimate co-development or exit partner. However, many clinical-stage, mid-sized pharmaceutical companies are actively seeking strategic partnerships to expand their pipelines, with many also establishing corporate venture funds to invest in areas that complement or go beyond their existing pipelines.

This panel will explore key questions, including:

- What are the advantages of partnering beyond big pharma?
- How does collaboration with a mid-stage company differ from working with Big Pharma?
- What makes a therapeutics company an attractive partner?

With numerous pathways available to advance novel therapies, it's essential for companies to consider all partnership opportunities. Panelists will share insights on what these collaborations look like, and how they can deliver mutual value for both the innovator and the pharma partner.

### Marc Appel, Managing Partner, Pacific Bridge NY



Marc Appel is a seasoned biotech investor and operator. He founded Orange Grove Bio, serving as CEO, and led portfolio companies IpiNovyx Bio and Asalyxa Bio. He has structured major deals with large pharma and served on multiple biotech boards. Marc advises university innovation programs including Yale, Michigan, Cornell, and Dartmouth. At Marathon Asset Management, he helped build the structured healthcare and royalty investing strategy, leading significant biotech deals. Earlier, he invested across the capital structure in public healthcare opportunities, including biotech, healthcare IT, services, insurance, and devices. His broad expertise spans company building, dealmaking, and strategic advising in the healthcare and biotech sectors.

### Salma Al-Zu'bi, Investment Principal, Hikma Ventures



Salma is an Investment Principal at Hikma Ventures (CVC arm of Hikma Pharmaceuticals PLC), where she focuses on strategic investments in biotech, diagnostics, and novel drug delivery mechanisms. She plays a key role in identifying high-potential opportunities that align with Hikma's portfolio strategy and future growth, while also facilitating partnerships with innovative companies to drive healthcare advancements. Salma began her career at Ernst & Young MENA, working in Corporate Finance and External Audit, advising clients across banking, retail, hospitality, and financial services. She specialized in financial due diligence, strategy consulting, and audit services. Prior to joining Hikma, she served as Senior Investments & Programs Manager at Beyond Capital Jordan, where she led the Fund of Funds pillar, managing direct investments into VC funds and capacity-building programs for emerging fund managers. Education: Salma holds a Bachelor of Arts in Banking and Finance from the American University of Madaba.

### Dirk, Büscher, Sr Director Grifols Innovation and New Technologies, Grifols



Dirk received his PhD in Biology in the area of Immunology from the University of Hannover, Germany, and focused his postdoctoral work at the Salk Institute, La Jolla, California, on molecular developmental biology and stem cell research. In 2004 he joined Cellierix SA, a Madrid-based cell therapy company, obtained an International Executive MBA from the Instituto de Empresa (ie) and from 2007 on occupied the position of Vice President of R&D. At Cellierix he had been in charge of the preclinical and CMC program, represented the company in several scientific advices at EMA, and served as industry expert on mesenchymal stem cells in EMA workshops. In 2010 Dirk accepted a position as managing director of Gri-Cel SA, a newly created fully owned subsidiary of Grifols SA, dedicated to advanced therapies and innovative therapeutic approaches. In 2015 he transferred to the newly created company GIANT and served on three boards of biotech companies, in which Grifols held a significant participation. Currently at GIANT Dirk is heading the scouting and evaluation of new platform technologies and opportunities in the pulmonary sector, as well as the technological vigilance related to Grifols' pulmonology franchise.

### Chloé Lepretre, Head of Global R&D Search and Evaluation, Servier



Chloé is Global R&D Search and Evaluation Director at Servier, leading external innovation scouting to support the pipeline and research platforms. With over 15 years of experience in life sciences business development, she joined Servier in 2018 to drive partnering in discovery and early development. Previously, she was Program Acquisition Manager at Onxeo, managing scouting, due diligence, and deal-making. She also worked at FIST, CNRS' tech transfer office, focusing on IP protection and licensing in neurology and rare diseases. Chloé holds a PhD in aging biology from Université Paris Cité and an MBA from IAE Paris Sorbonne Business School.

### Nicolas Stalder, Senior Investment Manager, Debiopharm Innovation Fund




Nicolas Stalder is a Senior Investment Manager at Debiopharm Innovation Fund, where he also serves on the company's Digital Transformation Committee. With three years of experience in strategic venture capital, he brings deep insight into scouting and integrating external innovation within corporate environments. Prior to joining Debiopharm, Nicolas held commercial strategy roles at GSK. His dual role enables him to bridge internal transformation with external opportunity, giving him a unique perspective on innovation adoption in complex organizations. Nicolas is also a board member / observer at both start-ups and scale-ups.

# 10:00 AM | AGING AND LONGEVITY PANEL

*Investing for Healthier Lifespans*

This panel will feature investors that focus on longevity. Learn about their investment preferences and how they evaluate and manage their relationships with their early-stage portfolio and prospects in this specific market. Hear from active age-tech experts on their predictions for the future of this sector.



**Fiona Miller**, Managing Partner, quadraScope Venture Fund 

Fiona is a serial entrepreneur with three successful exits, including a 12x return. She founded and led octoScope, acquired by Spirent in 2021; was Founder and CTO of Azimuth Systems, sold to Anritsu in 2016; and served as VP of Engineering at Scope Communications, acquired by Hewlett-Packard in 1998. She holds 21 patents and has authored numerous publications on wireless technologies. Fiona is also an active angel investor and philanthropist in the rejuvenation field. She earned a BA in Computer Science and a BS in Electrical Engineering from Columbia University and pursued graduate studies at MIT.



**Caleb Bell**, Advisor, Beyond Next Ventures

Caleb is a scientist, entrepreneur and venture builder launching and investing in early-stage deep tech startups globally. He currently supports investments at Beyond Next Ventures (Tokyo) and CE-Ventures (Dubai). He previously worked for Arcline, G4S Capital, Prime Movers Lab, Corundum and CTIC Capital. Caleb actively supports founders through board, mentorship, and pro bono roles with organizations such as StartX, Blockbuster Tokyo, UCLA Biodesign and Nucleate. He holds a Ph.D. in Biophysical Chemistry from Stanford, where he also attended the Graduate School of Business, and a B.S. in Biochemistry from Penn State. His interests include living medicines (cell, gene, microbiome), bio-inspired technologies, and the convergence of biology and computing.



**Bettina Ernst**, Director, BERNINA BioInvest

Bettina has over 8 years of experience investing in healthcare and serves on the boards of early-stage biotech companies in Switzerland, the Swiss Biotech Association, the Swiss Entrepreneur Fund, and the Innovation Council of Innosuisse. She co-founded two biotech startups and previously spent a decade in fundamental immunology research in the U.S. (Scripps Research Institute, San Diego) and Europe. Bettina holds a PhD in immunology and a degree in natural science from ETH Zurich. She is based in Switzerland.



**Ravi Mistry**, Venture Partner / Officer & Founding Team Member, 3i Partners

Ravi Mistry is a multifaceted leader, entrepreneur, investor, and mentor with experience spanning life sciences, technology, non-profits, and academia. He is currently Funds Management and Operations Officer at Impact India Investment Partners (3iPartners), investing in early-stage impact startups in India. He previously held leadership roles at MedTree LLC, IIT Gandhinagar Foundation, and was a founding team member at Virident Systems (acquired by HGST). His earlier roles include positions at DiscoveRx and Biomagene. Ravi is an active angel investor with TiE Angels and a former President of EPPIC Global. He mentors IIT GN alumni and engages with various Bay Area biopharma groups. He holds degrees from Gujarat University, Stanford University, and CSUEB.



**Jeremy Sohn**, Managing Partner, P74 Ventures

Jeremy is a venture investor, entrepreneur, and life sciences leader with 25 years of experience driving business model transformation. He is Managing Partner at P74 Ventures, a fund focused on platform technologies. Since 2013, he has completed 26 investments, led partnerships with over 100 start-ups and tech leaders, and developed eight transformational platforms. Previously, he was VP and Global Head of Digital BD&L at Novartis, overseeing digital health ventures, partnerships, and the Novartis Biome. Before that, he was Managing Director at MPM Capital, leading its pharma-tech fund. Earlier in his career, he co-founded Wasabi Systems, an open-source OS company, serving as CFO and VP of Business Development.



**Alex Strasser**, Senior Associate, Apollo Health Ventures

Alex joined Apollo as a Senior Associate in 2024, bringing over four years of experience as a healthcare investor focused on external investments. Based in Boston, he has supported companies from incubation to IPO, contributing to over \$3.7B in acquisitions. Previously, he was at RA Capital Management, where he led investments across cardiology, metabolic disease, oncology, and reproductive health, and served as a board observer for several portfolio companies. Alex holds a BSc in chemistry from Davidson College, where he was a Fulbright Scholar and NCAA Division 1 swimmer.

# 11:00 AM | HEALTH SYSTEM PARTNERS PANEL

*Novel Partnering Approaches to Improve Quality of Care*

Healthcare organizations are embracing innovations and becoming a key training ground to test the medical benefits, technical feasibility, and business viability of new technology breakthroughs. From innovation centers to investment vehicles, healthcare organizations have become critical partners for entrepreneurs. This panel will reveal the changing role healthcare organizations are playing in fostering innovation. Topics may include:

- What are hospitals and health networks doing to engage with new technology companies?
- How can a startup get the most out of conducting pilot studies with a healthcare system partner?
- How do early stage companies work with healthcare systems to generate user experience for their new technologies?
- How can healthcare organizations share their technical expertise with startups?

This RESI panel will help entrepreneurs navigate complex healthcare systems and bring their companies to the next milestone.

## **Jeff Stinson**, Director, HealthTech Arkansas



Jeff is the founder and leader of HealthTech Arkansas (HTA), which drives innovation for the state's largest hospitals and health systems through accelerator programs like HeartX and the Northwest Arkansas Biodesign Sprints. He has also launched six early-stage investment funds, including Fund for Arkansas' Future (FAF), the state's first angel group, which invested \$10.6M in 36 startups. From 2012 to 2015, Jeff directed UALR TechLaunch, boosting tech transfer and collaboration. He also founded the Delta I-Fund, a private I-Corps-style program. Jeff earned his MBA with honors from Vanderbilt's Owen School and has worked in private equity and health innovation since moving to Arkansas in 1999.

## **Eileen Flowers, PhD**, Director – Technology Development and Licensing, Memorial Sloan Kettering Cancer Center



Eileen Flowers, PhD, is a Director of Technology Development and Licensing in the Office of Entrepreneurship and Commercialization at Memorial Sloan Kettering Cancer Center (MSK). She leads MSK's Therapeutics Accelerator program which forms partnerships with companies to co-develop cancer therapeutics. Previously, Eileen was a Vice President on the biotechnology equity research team at Jefferies, focusing on oncology and rare diseases companies. She has also served as an equity research associate covering specialty pharmaceuticals at Piper Jaffray and a medical writer at BGB Communications, where she worked with pharmaceutical industry clients. Eileen received her bachelor's degree in biological studies from Columbia College and her PhD degree in cellular, molecular, and genetic studies from Columbia University.

## **Thomas Thornton**, Vice President, Innovation, Jefferson Ventures, Jefferson Health



Tom Thornton is Vice President of Jefferson Ventures at Jefferson, a \$14B enterprise spanning Jefferson Health, Thomas Jefferson University, and Jefferson Health Plans. He collaborates across the system to drive innovation that improves health outcomes, enhances patient experience, and creates new revenue. Previously, he was the founding SVP of Northwell Ventures, leading strategic investing, company creation, innovation management, and joint ventures to diversify revenue. Tom also serves as a board member and angel investor in healthcare startups, advises academic medical centers worldwide, and advocates for water quality initiatives on Long Island. He lives in Oyster Bay, NY, with his wife, Lindsay, and their five children.

# 1:00 PM | AI IN HEALTHCARE PANEL

## *Investing in the Intersection of Life Sciences and Technology*

This panel focuses on the many applications of AI in healthcare, from pathology applications to diagnostics to personalized medicine. Topics may include:

- What are investors looking for when evaluating companies in this space
- Where is AI in healthcare now and where is it going
- What are the current challenges facing AI, including regulatory challenges

In recent years, numerous technologies integrating AI have come up in the life sciences & healthcare industry. From drug discovery platforms to remote patient monitoring, AI plays a big role in a lot of the up and coming startups in this space. In this panel, we hope to uncover areas that pique investors' interests at this current time. In addition, panelists can discuss the associated risks, such as regulatory or ethical complexities, data quality, among others.



**Joe Collura, MBA, MS BIOE, Managing Partner, HelixPoint Capital (Moderator)**

Joe Collura is Managing Partner of HelixPoint Capital, a Cambridge-based venture firm operating at the intersection of life sciences and drug discovery automation. HelixPoint combines an automated R&D infrastructure with a pre-seed to Series A fund to build and scale biotech companies faster, with less capital, and greater conviction. Joe's background spans therapeutic commercialization, drug discovery & clinical R&D, and venture incubation, with a focus on accelerating drug development while reducing costs. He holds an MBA from Northwestern's Kellogg School of Management, an MS in Bioengineering from Northeastern University, and a BS in Biology from the United States Air Force Academy.



**Leo Cui, Partner, FoundersX**

Leo Cui is a General Partner at FoundersX Ventures, where he leads investments in healthcare and deep tech, with a focus on AI-driven innovation. With over a decade of research in microfluidics and CRISPR, he was a postdoc in Feng Zhang's lab at the Broad Institute and earned his Ph.D. from Harvard in David Weitz's lab. Leo holds six patents and has authored ten peer-reviewed papers. His work has led to two biotech spin-offs and a licensed patent to Quanterix (NASDAQ: QTRX). Passionate about the intersection of bioscience, engineering, and AI, his portfolio includes 1910 Genetics, Omniscope, Zafrens, Arintra, and Glyphic Bio.



**Ser-Chen Fu, Partner, Pacific 8 Ventures**

Dr. Ser-Chen Fu was previously trained as a clinical neurologist and served as an attending physician during his clinical practice. At Pacific 8 Ventures, he provides a clinical and medical perspective in assisting healthcare startups realize their visions. Dr. Fu is passionate about helping healthcare related startups, and believes the success of startups will determine the future of healthcare and medicine.



**Adam Steinert, CTO, Yahara Ventures**

Adam Steinert leads technology strategy as CTO at Yahara Software and Yahara Ventures, an investment firm focused on accelerating tech-enabled platform development in Biohealth. With two decades of experience in software engineering, Adam specializes in evaluating AI/ML solutions from both technical and investment perspectives. His hands-on work developing AI applications for image analysis, laboratory process, and workflow automation gives him unique insight into the implementation challenges in these environments.



**Bob Sweeney, DA, MS, MBA, Principal & Co-Founder, Global Health Impact Fund**

Bob Sweeney is one of a select group of proven national experts in the acquisition, management, evaluation and promotion of agreements between healthcare organizations and physicians. His areas of expert competencies include emergency medicine, neurological rehabilitation, home health care, managed care and the medical information needs of hospitals and physicians. His professional competencies include general and financial management, investment fund raising, executive sales and negotiations, direct response marketing techniques, sales management and public relations. Bob is also experienced in the commercialization of intellectual property developed in academic environments and the organization of academic and professional advisory boards.



**Sally Wang Liang, Managing Partner, Xpanse Venture**

Sally Wang Liang, JD, MPH, is Managing Partner at Xpanse Venture. She has over 20 years of experience in life sciences, biopharma, and healthcare, with previous roles as Partner at Highlight Capital and Venture Partner at Viva Bioinnovator, where she managed 11 portfolio companies. An active contributor to the biotech ecosystem, she serves on advisory boards at Harvard Medical School and the Boulder Peptide Foundation. Sally has held executive roles in digital health and therapeutics startups and practiced pharmaceutical patent law. She began her career in consulting and health policy. Sally holds degrees from Harvard College (AB), Harvard Law School (JD), and Harvard T.H. Chan School of Public Health (MPH).

# 2:00 PM | ALTERNATIVE FUNDING SOURCES PANEL


## *Funding Opportunities for Early-Stage Companies*

Venture capital gets a lot of attention, but it is not the only source of funding. This panel explores a diverse range of alternative funding sources for early-stage companies such as angel investors, family offices, grants, and more. Hear about the overlooked channels of capital and learn what these funders are looking for and how to access them. Topics may include:

- How does your approach to funding differ from traditional sources like banks or venture capital?
- What factors do you consider when evaluating funding opportunities?
- How do you see the landscape of alternative funding evolving in the next few years?
- What advice would you give to those seeking funding from organizations like yours?


This panel will open up new possibilities for an entrepreneur's funding journey. Because early-stage capital is not one-size-fits-all, thinking beyond traditional venture capital could be the key to unlocking a startup's next big move.

### **John Pennett**, Angel Investor, Mid Atlantic Bio Angels




John Pennett is Partner-in-Charge of the National Technology and Life Sciences Group at Eisner Advisory Group LLC and a member of Mid-Atlantic Bio Angels, an angel group focused on emerging life sciences companies. With 35 years of public accounting experience, he has led over 50 IPOs, private financings, and M&A deals totaling \$3B+. John also contributes to EisnerAmper's Catalyst newsletter and regularly writes and speaks on industry topics. He supports entrepreneurial organizations nationwide and mentors early-stage startups. His expertise spans auditing, risk advisory, Sarbanes-Oxley compliance, outsourced accounting, and international services. Previously, he was an Audit Partner at an international consulting firm.

### **John Abeles**, General Partner, Northlea Partners




Dr. John H. Abeles, BSc(Hons), MBChB, is a physician, pharmacologist, and seasoned biomedical investor. After earning medical and pharmacology degrees from the University of Birmingham (UK), he practiced medicine in London and Connecticut before holding senior roles at Sterling Drug, Pfizer, and USV. In 1975, he became Wall Street's first full-time MD securities analyst with Kidder Peabody. He later founded MedVest Group and Northlea Partners, focusing on biomedical venture capital. Dr. Abeles has backed numerous early-stage biotech companies, many of which went public or were acquired. He has served on advisory boards at UC Berkeley, Stanford, and the University of Kansas, and supports multiple healthcare and arts nonprofits globally.

### **Nicolas Cindric**, Partner, Yahara Ventures




Nicolas Cindric is a Partner at Yahara Ventures, an accelerator offering software development services to life science startups in exchange for equity. He also serves as a sell-side advisor at True North Mergers & Acquisitions, focusing on lower middle-market companies. Previously, he managed investments for the Cavill family office in Madison, WI, overseeing healthcare company acquisitions, growth, and exits. Nicolas holds degrees from the University of Notre Dame, Purdue University (MS, Management), and the University of Wisconsin (MS, Biotechnology). He is an active angel investor and board member for several healthcare companies.

### **Marc Estigarribia**, Sr Partner/ Managing Director, MSQ Ventures



Prashant is CEO of o2h discovery, General Partner at o2h ventures, and co-founder of the o2h group, which seeds innovation across life sciences and tech through funding, incubation, and services in chemistry, biology, and software. He led the award-winning Mill SciTech Park project in Cambridge, UK, where the group is headquartered with a presence in the UK, USA, and India. A serial entrepreneur since the dot-com era, he co-founded a drug discovery company acquired by a public firm. Prashant has funded and built nearly 50 startups and is a community builder and board member across biotech and tech. He holds degrees in engineering, robotics, and management from Cambridge University.

### **Prashant Shah**, Partner, O2h Ventures



Prashant is CEO of o2h discovery, General Partner at o2h ventures, and co-founder of the o2h group, which seeds innovation across life sciences and tech through funding, incubation, and services in chemistry, biology, and software. He led the award-winning Mill SciTech Park project in Cambridge, UK, where the group is headquartered with a presence in the UK, USA, and India. A serial entrepreneur since the dot-com era, he co-founded a drug discovery company acquired by a public firm. Prashant has funded and built nearly 50 startups and is a community builder and board member across biotech and tech. He holds degrees in engineering, robotics, and management from Cambridge University.

# 3:00 PM | CNS DISEASES PANEL

*Latest Innovations and Investment Trends*

CNS Diseases can affect anyone, from children suffering from genetic disorders to elderly suffering from neurological diseases such as dementia in all its forms, as well as mental and behavioral disorders, that can appear at any age. Investing in technologies relating to CNS disorders remains high, among the most well-funded indications. Panel topics may include:

- What areas of CNS are saturated and what areas need more attention?
- What are common red flags seen when investing?
- What makes a company stand out in CNS?

As much as treating CNS diseases has been in the forefront for decades, investors are still seeking innovation, whether new and more complex therapeutics that can cross the blood-brain barrier, new treatments and preventions for neurodegenerative diseases, better diagnostic tests and treatments for mental and behavioral health, or devices that can restore function, among others. The more researchers learn, the greater the mystery of the central nervous system; panelists will discuss what are the newest and most exciting innovations in the CNS landscape.



**Zizi Imatorbhebhe**, CEO & Executive Partner, Bios Health Group

Zizi Imatorbhebhe, MBA MS PMP® is the CEO of Bios Health Group, a strategic partner for both Life Science companies and Investors with offices in Atlanta, Georgia and Irvine, California. Zizi has over 30 years' experience in the Life Science and Biotechnology industry working across functions including investment, clinical development, and commercial strategy. Her passion is to help successfully guide biotech and life science companies to overcome hurdles faced in these areas.



**John Boyce**, Managing Director & Co-Founder, 28 Capital

John is a genomics and proteomics entrepreneur specializing in therapeutics and building companies for acquisition or IPO. Recognized in 2013 as one of Massachusetts' top 15 Technology Luminaries, he has raised over \$800M and achieved exits totaling more than \$1.8B. As President and CEO of Exosome Diagnostics, he turned around the struggling liquid biopsy firm, implementing a "3 Pillar Strategy" and securing key investments—leading to its \$575M acquisition by Bio-Techne within 2.5 years, delivering a ~6x return. John is also Co-Founder of Tiger Gene, backed by Tiger Management. A Fellow at Harvard, he teaches "Entrepreneurship and Innovation" to 400+ students in Sanders Theater.



**Danny Carbonero**, Investor, PsyMed Ventures

Danny Carbonero is an Investment Associate at PsyMed Ventures, where he supports early-stage companies in neurotechnology, brain health, and human-focused neuroscience. A biomedical engineer turned investor, he earned his Ph.D. in computational neuroscience at Boston University, where his NIH F31-funded research applied machine learning to large-scale neural data. Prior to PsyMed, Danny was a Venture Fellow at Breakout Ventures, focusing on creative bioscience startups. He also served on the leadership team at Nucleate Boston and worked as a Student Analyst in BU's Office of Technology Development. He holds a B.S. in Biomedical Engineering from the University of Miami, where he developed robotic tools for disease modeling and drug discovery.



**Cheryl Kuai**, Managing Director, Sixty Degree Capital

Cheryl Kuai is Managing Director at Sixty Degree Capital, a Toronto-based venture capital firm focused on healthcare. She invests in biotech and healthtech companies with strong clinical profiles and the potential to improve patient outcomes. Cheryl has led investments in notable firms such as GlycoEra, Seawolf, Nested Therapeutics, and CinCor Pharma (acquired by AstraZeneca). She brings a unique blend of scientific and financial expertise as a CFA charterholder with a Ph.D. in Biotechnology, driving impactful investments in the healthcare sector.



**Yogesh Dayma PhD**, Venture Partner, 1004 Venture Partners

Yogesh Dayma PhD, is a seasoned expert in healthcare investments, specializing in Biopharmaceutical, life sciences and MedTech sector. With a focus on private fundraising, company formation, M&A, and advisory services, he has successfully executed over 25 transactions, including several cross-border deals, for both public and private life sciences companies. Dr. Dayma completed his research training at the prestigious Koch Institute at MIT and has authored numerous scientific publications. Transitioning from academia, Dr. Dayma ventured into Wall Street investment banking sector, where he excelled in healthcare and life sciences investments.

# 4:00 PM | MEDICAL DEVICES PANEL

## Latest Trends in Medtech Investments

The medical device industry continues to experience rapid growth, driven by technological innovation, regulatory advancements, and increasing global healthcare demand. This panel brings together active investors to discuss the latest trends, opportunities, and challenges in the medical device industry. Topics addressed may include:

- Emerging technologies and current trends that excite investors
- Investment strategies and due diligence process on medical device opportunities
- Navigating regulatory hurdles and barriers to market entry
- Case studies of successful medical device investments

This panel will be an insightful discussion on how investors capitalize on this dynamic sector while driving advancements in patient care and medical technology.

### Ralph Morales III, Venture Partner / Executive-in-Residence, Aquillius Ventures



Ralph Morales III is a strategic innovator with over 15 years of experience at the intersection of medical devices, AI, and predictive health. He has led the development and commercialization of wearable tech and machine learning tools for early detection, chronic care, and behavioral health. At Oura, he spearheaded healthcare partnerships and AI strategy, translating biometric insights into clinical outcomes. His work spans CPAP-integrated sleep tech, biometric signal processing, and multi-modal sensing. Ralph now advises medtech firms and startups on AI diagnostics, personalized health, and compute infrastructure, focusing on bridging devices, data, and decisions to accelerate health breakthroughs.

### Ayah Hamdan, Director & Ventures, Health, Plug and Play



Ayah Hamdan was born and raised in the Bay Area, having a front row seat to Silicon Valley's tech and innovation growth. Ayah holds a Bachelor's degree in Public Health from UC Berkeley and a Master's in Epidemiology from the Harvard School of Public Health. While at Harvard Ayah launched her own startup through the iLab, which was a consulting and implementation service focused on bridging digital health solutions to refugee women users. Ayah also previously served in a leadership role at Carbon Health during their Series B to C growth stage, launching the country's largest COVID-19 testing and vaccination sites. Currently, she is the Head of Health at Plug and Play ventures, driving their early stage digital health investments and corporate partnerships with pharmaceutical companies, health systems and MedTech industry leaders.

### Daniel O'Mahony, Partner, Seroba Life Sciences



Daniel O'Mahony is a Partner at Seroba and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation. Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He was an advisor and consultant to Kernel Capital venture capital fund from 2001 and a partner from 2008, focusing on investments in life sciences. He joined Seroba as partner in 2009. Daniel has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA, and the Department of Medicine & Experimental Therapeutics at University College Dublin. He established Technology Transfer Office at University of Galway, leading to several lucrative licensing deals (2005-2007). He has published in several scientific journals and is co-inventor on numerous patent families.

### John Tremblay, Investor, Launchpad Venture Group



John is an angel investor with LaunchPad Venture Group and leads the digital health innovation consulting practice at Healthy Context, LLC. He helps organizations implement transformative healthcare solutions that set new standards in care delivery. Formerly VP of Digital Strategy & Portfolio at Fresenius Medical Care's \$5B MedTech renal division, he helped launch two life-saving home therapies now serving over 34,000 U.S. patients. John has also served as an NSF I-CORPS instructor and co-led a university lean innovation incubator for deep tech spinouts. He holds a BS in electrical engineering and an MBA in technology innovation from Northeastern University.

# 4:00 PM | MEDICAL DEVICES PANEL

*Latest Trends in Medtech Investments*



**Chris Yoo**, General Partner, Xcellerant Ventures

Chris has 25+ years of experience in advancing biomedical technologies. He is Regional Innovation Officer for the MDM2 Consortium in Phoenix and Managing Director of Xcellerant Ventures, Arizona's HealthTech-focused VC fund. A serial entrepreneur and angel investor, Chris has founded and led companies in oncology, cognitive computing, and personalized medicine. He actively supports startups through Yoo & Co Accelerators and mentorship at ASU, where he also teaches molecular diagnostics, bioengineering, and entrepreneurship. Chris holds a Ph.D. from Yale, completed a postdoc at UC Berkeley, and earned a B.A. from the University of Pennsylvania. He has also worked with Cisco, Oracle, and IBM on early personalized medicine strategies.



**Mark Vreeke**, Co-Founder, Chemical Angel Network

Dr. Vreeke is cofounder of the Chemical Angel Network, which funds early-stage hard science startups in materials, measurement, and manufacturing. He also leads TransAtlantic Science, offering services such as IVD prototyping, interim CTO support, and corporate venture structuring. Previously, he was VP of R&D at Rational Biotechnology and Senior VP at Pepex Biomedical, both focused on advancing personalized medicine and biosensor technologies. Earlier, he held research roles at TheraSense, contributing to one of the most successful non-drug university tech transfers. Dr. Vreeke holds a PhD in analytical chemistry from the University of Texas and a BS from Calvin College. He serves on various boards and is a visiting professor in Spain.



**Don Zinn**, US Vice President US Business, Crossject

Don brings over 30 years of experience in building biotech, pharmaceutical, and medical device companies from the ground up. He currently leads Business Development at Crossject, a publicly traded French company transforming emergency drug delivery with its needle-free ZENEO auto-injector. Don has held key roles at Rentschler Biopharma, SciTech Development, Microbion Corporation, Aursos, AzoRx, and others. He also serves as a commercialization grant reviewer for the NIH under the CRP program and actively mentors startups through various university research initiatives.

# 9:00 AM - 4:50 PM | INNOVATOR'S PITCH CHALLENGE TRACK 1

Location: Essex Northwest

## Pitch Company

9:00 - 9:50 AM  
SESSION #1  
MEDICAL DEVICES



Table #18



Table #24



Table #3



tissuelabs

Table #11

10:00 - 10:50 AM  
SESSION #2  
R&D / LIFE SCIENCE  
TOOLS



Table #44



Table #30



Table #8



Table #12

11:00 - 11:50 AM  
SESSION #3  
THERAPEUTICS



Table #16



Table #9



Table #42

1:00 - 1:50 PM  
SESSION #4  
THERAPEUTICS



Table #41



Table #1



Table #20



Table #6

2:00 - 2:50 PM  
SESSION #5  
MEDICAL DEVICES



Table #22



Table #49



Table #38



Table #37

3:00 - 3:50 PM  
SESSION #6  
DIAGNOSTICS



Table #45



Table #47



Table #10



Table #48

4:00 - 4:50 PM  
SESSION #7  
THERAPEUTICS



Table #15



Table #53



Table #29



Table #28

## 9:00 AM | SESSION 1 - MEDICAL DEVICES



40% - 59% of blood transfusions are unnecessary, and needlessly harm patients. Coagulation Sciences', a pre-revenue clinical company, has developed the fully automated Multiple Coagulation Test System (MCTS). Advanced information reported by the MCTS in ~ 10 minutes, at the Point-of-Care (POC) indicates how to best stop bleeding and minimize unnecessary transfusions. The platform is easily modified to create a menu of single-use cartridges for cardiac surgery, post-partum hemorrhage, trauma surgery, liver transplant surgery, and assessment of novel anticoagulants. Revenue in year five of sales is projected to reach \$200M.



Cobionix is developing CODI®, the world's first autonomous robotic healthcare assistant designed for procedural tasks, starting with automating diagnostic ultrasound procedures. As one of only three medically certified collaborative robots globally—and uniquely certified for various procedural tasks—CODI® combines advanced vision and AI-driven ultrasound capabilities to autonomously perform ultrasound exams across multiple organs. This innovation directly addresses the \$25B U.S. market, heavily dependent on skilled sonographers, by democratizing ultrasound access initially in underserved rural regions lacking healthcare resources. With a robust pipeline of early adopters, Cobionix anticipates significant market growth beginning Q4 2025, progressively expanding CODI®'s impact in ultrasound diagnostics globally.



Kilele Health will be the sole provider of wearable blood chemistry sensors that combine longevity (lasts 10+ days) with variety (can measure many biomarkers or drugs). Our SunVida system, protected by 50+ pending patents, will migrate chronic disease management from crisis-based care to status-based care by giving patients and care teams actionable real-time data, preventing crisis & improving outcomes while dramatically reducing costs. The sensor mimics the proven form factor of continuous glucose monitors - a small painless device worn on the arm or abdomen. Kilele has 3 applications in development: phenylalanine (Phe) to manage pediatric phenylketonuria (prevent permanent cognitive damage), NT-proBNP, potassium (K), and creatinine (Cre) to manage heart failure (prevent hospital readmissions, a \$16B problem), and Phe, K, Cre, and lactate to manage the most intense multi-chronic patients with an early warning (shift care from ER and hospital to clinic, a 10% shift = \$100B savings).



TissueLabs, a Swiss startup, is tackling one of the most pressing challenges in drug development and regenerative medicine: the lack of human-relevant tissue models. Currently, 90% of drugs fail in clinical trials, largely because preclinical testing relies on outdated models such as 2D cell cultures and animal testing, which fail to accurately mimic human physiology. Our proprietary biofabrication platform addresses this issue by enabling the creation of biomimetic human tissues, reducing reliance on animal models, and significantly improving the accuracy of preclinical drug screening.

## 10:00 AM | SESSION 2 - R&D / LIFE SCIENCE TOOLS



In-dwelling devices are responsible for up to 60% of hospital acquired infections, costing billions in direct healthcare costs and tens of thousands of lives. Antimicrobial devices have been shown to help lower infection rates but typically double the cost the device. At Inhibit our goal is produce antimicrobial medical devices without increasing the cost the device. We do this through our novel antimicrobial polymers, based on existing medical grade polyurethanes, which have high broad-spectrum antimicrobial efficacy while being proven to be non-leaching and non-toxic. The low cost material as a drop-in replacement removes the need for complicated coating processes, offering savings in both material cost and manufacture. Inhibit is seeking device partners looking to have an impact in reducing device infection rates and improving patient outcomes.



Novel has developed world's first patent protected Vibrio Nat. based DNA cloning host (CyClone) and pDNA manufacturing platform (NBx). The platform offers 3X cloning speeds, up to 10X yields, remarkable stability with challenging DNA designs and better quality profile than traditional E. coli based platforms. Novel is revenue generating company with multiple revenue streams that include manufacturing pDNA for its clients, sale of CyClone product and licensing NBx to Biotech companies. Novel has increased its pDNA manufacturing revenue by 200% YoY from last year and on track to do the same this year, signed a term sheet with Ceva to license NBx to manufacture mRNA vaccines globally and launched its early access program for CyClone in May at SynBiobeta and got phenomenal response. Novel is seeking to raise \$2-4M to expand its manufacturing capacity and expects to break even in 2026.



Pando Bioscience combines advanced AI models with ultra-high-throughput wet lab screening to design and optimize enzymes for pharmaceutical, diagnostic, and synthetic biology applications. Through its proprietary PDTM™ platform, Pando delivers custom enzymes with superior activity, selectivity, thermostability, and manufacturability. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our AI models to efficiently optimize enzymes across multiple properties, delivering high-performing, industrial-grade enzymes that create and capture new market value.



Qnity is currently at the pre-revenue stage, having developed and validated our quantum electrochemical platform for molecular affinity assays, with initial pilot projects underway with pharmaceutical partners and research institutions. We are now transitioning from technology validation to scaling pilot deployments and generating early revenues as early as 2027. To support this next phase, we are seeking \$850k in Pre-Seed+ funding, which will enable us to expand our pilot programs, establish our Lab operations in the US, optimize our platform for broader drug discovery applications, pursue more LOIs from interested parties, and prepare for full-scale commercialization. Our plan moving forward includes expanding strategic pilots with pharmaceutical companies and CROs, scaling up manufacturing and deployment capabilities, strengthening our R&D pipeline to broaden into biomarker detection and screening, and preparing for a larger Series A round to accelerate global market entry and partnerships in 2027.

## 11:00 AM | SESSION 3 - THERAPEUTICS



BTB Therapeutics is a clinical-stage drug development company. Its programs include BTB-101, a non-opioid analgesic for acute pain, and transcriptomic drug discovery programs for rare genetic disease therapy and immuno-oncology. BTB Highlights: Robust Pipeline to address significant unmet needs; BTB-101 (ENDOPIN): non-opioid analgesic compound in clinical trials for post-op pain; BTB-101: Cancer pain, OA pain, and Pruritus (additional indications) ; BTB-1XX (ENDOPIN backup compounds): Joint discovery program with Kyoto University; Transcriptomics drug discovery (RNA splicing targeted small molecules); BTB-201/202: Cardiac Fabry disease, Long QT syndrome, and other genetic rare diseases; BTB-301: Enhance cancer neo-antigen gene expression; Raised \$41.4 mm (Equity/CN financing/non-dilutive grants) to date; Experienced Leadership Team with track records; HQ in San Diego, CA: R&D operation in Kyoto, Japan



Ceria Therapeutics, Inc. (Ceria) is a pre-clinical biopharmaceutical development company with facilities in Tucson AZ, Aurora CO, and San Juan PR. The company is advancing a pipeline of RNA-interference (RNAi) drug products using a next-generation RNA delivery platform to target severe inflammatory conditions in the critical care, GI, and advanced wound care markets representing a >\$35B market opportunity in the US alone. Ceria's products deliver a potent regulatory RNAi that rapidly blocks cytokine-induced inflammation, the cause of multiple inflammatory conditions. Unlike other failed attempts to target individual cytokines, our pipeline attacks upstream activators of the NF-kB pathway to block multiple inflammatory cytokines. In multiple models these assets demonstrate strong potential to durably correct disease. The company has raised ~\$20M in non-dilutive capital from DoD and NIH sufficient to result in two INDs. Ceria is now raising a syndicated \$12M Series Seed equity round to begin clinical development.



InnoPath Therapeutics is a drug development company developing first-in-class and best-in-class transformative topical therapeutics to treat the tens of millions of people who get Actinic Keratosis and Non-Melanoma Skin Cancer every year. We are accelerating the development of three novel formulations and a portfolio of patents that will be through Phase II of the FDA process within five years. We are a group of dedicated scientists, physicians, and business professionals with decades of preclinical and regulatory experience. Our experience includes successfully introducing more than 125 drugs, biologics, and devices through the FDA process and into patients, and returning more than \$1B to shareholders through successful exits. We are currently in the pre-clinical stage of our company and hitting all of our milestones.

## 1:00 PM | SESSION 4 - THERAPEUTICS



Adeno is a Massachusetts-based biotechnology company pioneering a first-in-class therapeutic platform for the treatment of familial adenomatous polyposis (FAP) and metastatic colorectal cancer (mCRC). Our lead candidate, AD101, is designed to selectively eliminate Wnt-driven tumors without toxicity. Adeno's preclinical studies have demonstrated a remarkable efficacy and safety profile in treating adenomas and CRC. Our CEO, Dr. Joe Sedlak, is a Harvard-trained MD/PhD and a second-time biotech founder. At his prior company, Mercy BioAnalytics, he served as the founding CEO, guiding Mercy BioAnalytics to raise over \$68 million. Mercy is recognized for its pioneering work in liquid biopsy for early cancer detection. Adeno is currently raising a \$12.5 million seed round to fund the clinical development of AD101, with plans to achieve clinical proof-of-concept by mid-2027. We're seeking strategic partnerships and investors who share our commitment to revolutionizing the treatment of FAP and colorectal cancer.



Cellertz Bio is an mRNA therapeutics company combining cutting-edge artificial intelligence and physics-based models to unlock the full potential of mRNA medicines. Our proprietary platform systematically explores the vast mRNA sequence space to design optimized mRNA molecules with superior stability, translation efficiency, and protein expression—enabling a new generation of high-performance mRNA therapies. Beyond platform licensing, Cellertz is building a differentiated therapeutic pipeline focused on in vivo immune cell engineering to treat cancer and autoimmune diseases. These programs offer scalable, off-the-shelf alternatives to cell therapies and can be monetized through strategic partnerships, co-development deals, or out-licensing. With a dual business model spanning platform and therapeutic pipeline, Cellertz is uniquely positioned to create value at the intersection of AI, synthetic biology, and next-generation immunotherapy.



Duo Oncology, founded by oncologists, is building a stronger, safer foundation for cancer medicine by replacing toxic chemotherapy with patient-responsive therapeutics. Duo's proprietary drug chemistry assembles potent molecules into nanomedicine complexes that bypass healthy organs and penetrate hard-to-treat tumors, such as those found in patients with pancreatic cancer. Their lead product, DUO-207, has demonstrated superior efficacy and safety compared to standard therapies in GLP toxicology studies. Supported by early investments from BeiGene Pharma, which acquired a 40% stake in Duo's seed round, and an \$8M follow-on term sheet from Prevail Partners, Duo Oncology is well-positioned to initiate clinical trials for DUO-207 in early 2025. The company's potential is further underscored by a Prix Galien nomination, two Orphan Drug designations, and over \$800,000 in NIH grants. Duo is currently raising investment to fund its first clinical trial and advance additional candidates in immunotherapy and precision medicine toward the clinic.



SONIRE is a Tokyo-based startup founded in February 2020, developing an ultrasound-guided HIFU (High-Intensity Focused Ultrasound) therapy system called "Suizenji," based on innovative technology from Tohoku University. Suizenji delivers focused ultrasound energy from outside the body, enabling non-invasive treatment without skin incisions or organ removal. It also allows treatment without anesthesia and carries no risk of radiation exposure. SONIRE is currently conducting a clinical trial for pancreatic cancer in Japan and preparing to initiate a U.S. clinical trial in 2025. Suizenji has been designated as a Breakthrough Device by the FDA for the treatment of pancreatic cancer. In addition to pancreatic cancer, SONIRE is planning clinical trials for additional indications within Japan. The company aims to address serious unmet medical needs by offering a safe, minimally invasive treatment option, and is actively seeking partners and investors as it advances toward commercialization.

## 2:00 PM | SESSION 5 - MEDICAL DEVICES



Auctus is developing a dynamic vertebral body tethering system to treat pediatric scoliosis with a magnetically adjustable implant. The system is designed with input from KOLs to specifically address this important treatment option for adolescents who otherwise would be facing complex fusion surgery. The system allows both freedom of movement and growth of the child's spine after surgery. Most importantly, the surgeon can adjust the tension on the implanted device non-invasively at any time so that the tether can grow with the child. This novel therapy has been developed by an accomplished team of business professionals with several successful exits (\$1.75B in investor returns) and extensive experience with start-up medical device development in this market including previously commercializing an expandable interbody fusion cage which was acquired by Stryker Spine at a 16X multiple. No child should choose between their health and an active life.



EncephalX is committed to redefining the standard of care for patients suffering from traumatic brain injuries or strokes. In cases of severe brain swelling, the current approach requires removal of a large portion of the skull to allow the brain to swell safely. This exposes the brain under the skin and requires a second surgery weeks later to replace the bone or insert a permanent implant. These procedures are invasive, risky, and often result in complications or prolonged recovery. Our solution, the Dynamic Cranioplasty System (DCPS), is a groundbreaking device that allows the skull to expand and contract in response to brain swelling, all within a single streamlined procedure. By eliminating the need for two surgeries, DCPS reduces risk, shortens hospital stays, and preserves the skull's natural protection. With a diverse team in neurosurgery, engineering, research, and regulation, EncephalX is delivering real-world innovation to improve lives and advance neurosurgical care.



Endeavor Orthopaedics, headquartered in Tulsa, Oklahoma, is a medical device company dedicated to innovating orthopedic trauma solutions, particularly for complex avulsion fractures. Founded by an experienced orthopedic surgeon, the company integrates surgical, engineering, and commercial expertise to develop clinically impactful devices. Their flagship product, the FDA-cleared Summit Patella Plating System, is the industry's first sterile-packed, single-use kit that combines plate, screw, and suture components, enabling comprehensive repair of both bone and soft tissue in patella fractures. Looking ahead, Endeavor aims to expand its product line to address fractures of the olecranon, greater tuberosity, and greater trochanter, targeting the broader U.S. avulsion fracture market, which is estimated at over \$2 billion annually.



InSight Surgical Technologies, Inc. (IST), is a late development phase, medical technology company developing products to provide real-time, ML/AI-enhanced, intraoperative guidance via image updating and quantitative fluorescence to enable faster, less invasive, more accurate, personalized treatment of tumors and to improve the clinical outcomes of standard, robotic and potentially all (e.g., non-cancer) surgical resections. IST's lead product in development, Intraoperative Image-updating Navigation (I2 Update™), will provide seamless, unobtrusive, accurate image updates of the evolving neurosurgical field. I2 Update™ leverages intraoperative stereovision (iSV) cameras mounted on standard operating microscopes that capture real-time images of the operating field. IST's proprietary algorithms incorporate optical data and pre-operative CT/MRI scans in a deformable 3D model that generates on-demand, accurate image data sets for image-guidance during surgery. I2 Update™ will integrate with leading surgical navigation systems to guide brain tumor resection precisely and enhance surgical treatment.

## 3:00 PM | SESSION 6 - DIAGNOSTICS



Adjuvant Genomics delivers actionable predictive insights to personalize cancer treatment. Our Lab developed test, a unique dual-predictive 12-gene assay combined with a machine learning (ML) algorithm, supports treatment decisions in early-stage non-small cell lung cancer (NSCLC), and we are actively developing further assays targeting additional cancers and therapies. We predict disease recurrence risk and response to adjuvant chemotherapy, enabling oncologists to personalize treatments for improved outcomes. With proper funding and data from therapeutic manufacturers, Adjuvant Genomics can further develop additional assays for other cancers and evaluate responses to immunotherapies, offering a versatile platform for targeted treatment decisions.



GuideAI Health is transforming cardiovascular diagnostics with an advanced AI platform designed to augment and enhance radiologist expertise. Created by interventional radiologists and AI/ML experts, GuideAI's cutting-edge algorithms identify subtle overlooked disease markers, reducing diagnostic errors and improving patient outcomes. GuideAI's exclusive partnership with vRad gives it access to one of the world's largest imaging datasets, significantly boosting model accuracy and validation. GuideAI Health's SaaS platform focuses on early detection of Peripheral Vascular Disease (PVD), a condition affecting 230M+ people globally. PVD is frequently misdiagnosed, leading to adverse cardiovascular events (including amputation), and costly complications. GuideAI Health translates raw imaging data into structured reports, fully integrated into existing workflows, providing actionable insights that enhance surgical precision and drive personalized care.



Supercharging routine blood exams with Artificial Intelligence, Huna turns massive data into accessible cancer care. By partnering with global leaders and leveraging one of the world's largest oncology datasets, we deliver scalable solutions using the world's most common blood exams. Our platform supports the full cancer journey—from triage to diagnosis and beyond—transforming standard lab data into powerful clinical insights. Huna makes cutting-edge innovation usable by real-world healthcare systems tackling one of the world's biggest health challenges.



MantaBio is a life sciences tools company building automated microbial detection systems specifically designed for biopharma manufacturing environments. Our platform offers rapid, high-sensitivity detection across all microbe categories: bacteria, fungi, viruses, and mycoplasma — delivering results in just 2 hours compared to the industry standard of 5 to 28 days. Built with the needs of biologics producers in mind, MantaBio's technology is optimized for speed, accuracy, and ease of use. It requires less than one minute of hands-on time, no specialized training, and integrates seamlessly into GMP workflows. By enabling at-line or near-line testing with gold-standard sensitivity, MantaBio helps manufacturers reduce contamination risk, minimize batch loss, and accelerate product release timelines. Our system is the next generation in microbial quality control — replacing outdated manual culture methods and reliance on off-site reference labs with a modern, automated approach built to match the pace and complexity of today's biopharma processes.

## 4:00 PM | SESSION 7 - THERAPEUTICS



Emervax is developing circular RNA vaccines and therapeutics to treat infectious diseases, cancers and autoimmune diseases. Emervax has developed a proprietary circular RNA platform called emxRNA which results in high circularization of the RNA at the start, an efficient and cost-effective purification method, novel thermostable nanoparticles and proprietary administration methods using microneedle patches. Emervax is supported by Coalition for Epidemic Preparedness (CEPI) and the NIH. Emervax's first vaccine for Yellow Fever will be in the clinic by the end of 2026, with additional vaccines and therapeutics entering the clinic in 2027 and 2028.



Neobe is a preclinical startup using synthetic biology to break down fibrotic barriers around solid tumors, enabling curating responses to existing drugs. Our technology is based on safe strains of tumor colonizing bacteria that are engineered with synthetic biosensors to ensure their tumor specific activity. By locally removing barriers to infiltration in tumors without affecting healthy tissues, our products can function as universal APIs for cancer treatments, enabling responses to different forms of precision therapeutics such as checkpoint inhibitors, antibody drug conjugates, bi-specific T cell engagers and cell therapies.



NERx Biosciences is a pre-clinical oncology company whose mission is to realize the full therapeutic potential of targeting the sensors that initiate the DDR. We have programs targeting RPA, Ku and other undisclosed DDR sensors. Our lead asset targeting RPA, NERx-329, demonstrates a robust mechanism of action as a competitive inhibitor of DNA binding. The asset displays robust single agent anti-cancer activity, and in vivo efficacy in combination with other DDR targeted therapeutics. Additionally, specific genetic predictors of RPAi sensitivity have been identified which will allow the selection of patient populations likely to benefit from RPA-targeted therapeutics, setting NERx-329 and our other molecules under development apart from the multiple DDR targeted therapeutics currently under development. Right behind RPA, we have a robust discovery pipeline of first-in-class DDR programs, the most advanced being a class of SMI that impair NHEJ through a completely novel mechanism.



ReEngage Therapeutics is a biopharmaceutical R&D company focused on developing therapeutics that treat longevity-related diseases. ReEngage does this by modifying epigenetic targets that are implicated in aging-related disorders, including neurodegeneration and cancer. We have developed novel small molecule inhibitors to a metabolic target, acetyl co-A synthetase (ACSS2), which is known to fuel epigenetic gene regulation. We have shown that our molecule MTB-9655 is safe and tolerable in humans, and now have elucidated its mechanism of action - downregulating expression of DNA damage repair genes, which contribute to chemo resistance. Further, MTB-9655 plus chemo in colorectal cancer (CRC) patient-derived xenograft models was shown to extend median survival by 50% over chemo-alone. We plan to initiate a phase 1b/2a study for third line metastatic colorectal cancer in 2026, led by PI Dr. Scott Kopetz of MD Anderson.

# 10:00 AM - 4:50 PM | INNOVATOR'S PITCH CHALLENGE TRACK 2

Location: Essex Northeast

## Pitch Company


9:00 - 9:50 AM  
**SESSION #8**  
**MEDICAL DEVICES &  
DIGITAL HEALTH**



10:00 - 10:50 AM  
**SESSION #9**  
**THERAPEUTICS**



11:00 - 11:50 AM  
**SESSION #10**  
**MEDICAL DEVICES &  
DIAGNOSTICS**



1:00 - 1:50 PM  
**SESSION #11**  
**MEDICAL DEVICES**



2:00 - 2:50 PM  
**SESSION #12**  
**THERAPEUTICS**



3:00 - 3:50 PM  
**SESSION #13**  
**THERAPEUTICS**



4:00 - 4:50 PM  
**SESSION #14**  
**THERAPEUTICS**



## 9:00 AM | SESSION 8 - MEDICAL DEVICES & DIGITAL HEALTH



Alleviate is the first and only organization that offers a fully integrated conservative management of musculoskeletal soft tissue joint pain used in the convenience of the home. It proposes therapeutic and preventative devices combined with an app-based guided recovery process, and captures pain and function patient reported outcomes. Evidence derived from the use of the app shows that a daily regimen of 10 minutes of guided exercises accomplished at home allows 85% of patients to achieve significant pain reduction. The data also demonstrates 50% to 70% improvement in pain at 6 weeks.



Allotex is revolutionizing vision correction with TransForm™—the first-ever human collagen-based implant for presbyopia, a condition affecting over 2 billion people worldwide. This game-changing solution restores near vision by adding natural tissue to the eye through a 10-minute outpatient procedure. With 135 million eligible patients in the U.S. and EU, we are unlocking a \$500M+ annual revenue opportunity. Clinically proven, TransForm™ has launched in Europe, Canada, and other key markets. Our proprietary platform enables expansion into broader vision indications and younger patient populations. Allotex combines the precision of optics with the power of biologics—offering a natural, reversible alternative to spectacles and contact lenses. Led by seasoned executives with successful exits, we have completed our Series B-2 and are now seeking a \$3M SAFE/Convertible Note to accelerate growth and position the company for a strategic exit or Series C. Be part of the future of vision—naturally, safely, scalably.



We are a bioinformatics-based precision medicine platform company translating patient-specific and population-based medical big data into novel pharmacological clinical treatment decision support products and services. We offer a proprietary technology, the PredictMed Platform, designed to help clinicians and health systems optimize precision in the selection of appropriate medications, drug combinations and dosages that improve each patient's health, while also reducing adverse reactions. Our PreciMed platform represents a significant step forward in accurately assessing a patient's complete medication profile. Physicians can finally see the full spectrum of medications present in the patient, and identify appropriate dosing levels for therapeutic effectiveness. PreciMed can accurately assess prescribing trends, medication adherence and EHR coverage, as well as define medication concentrations in patients with comorbid disorders.



The xBxBIO Platform is a groundbreaking digital healthcare solution that advances clinical decision support by fusing advanced artificial intelligence, machine learning, and quantum computing techniques with comprehensive multimodal data integration. The company's first commercial product, the "Cardiologist in a Box(tm)" dramatically enhances the diagnostic and analytic capabilities of traditional Holter and Mobile Cardiac Telemetry (MCT) devices. What is disruptive about this new technology is it will support the cardiologist and associated technicians and staff with best practice evidenced based information from big data to Increase Accuracy (Specificity & Sensitivity) from 50% to over 90% with Diagnostic, Analytical, Descriptive, Predictive & Prescriptive recommendations for various remedies and treatments to address the patient's situation. It will also have follow-on reimbursement codes for Revenue Generation."

## 10:00 AM | SESSION 9 - THERAPEUTICS



Amarna Therapeutics has developed Nimvec™, a unique non-immunogenic viral gene delivery platform derived from simian virus 40 (SV40), to deliver any transgene into humans without triggering immune responses. This technology enables the development of transformative, potentially curative gene therapies for both rare and common diseases, including genetic disorders, autoimmune diseases, and chronic inflammation. The lead candidate, Nimvec™ AM510, is designed to treat Type 1 Diabetes by restoring immune tolerance to proinsulin, aiming to halt the autoimmune destruction of insulin-producing  $\beta$  cells and potentially cure the disease. Unlike other gene therapies, Nimvec™ does not induce strong immune reactions, allowing for repeat dosing and improved efficacy. The platform's versatility and safety are supported by promising preclinical results, positioning Amarna at the forefront of next-generation gene and immunotherapies.



Baylink Biosciences is an biopharma company focused on development of transformative therapeutics to treat cancer. Baylink is developing next generation antibody drug conjugates with innovation and precision to enable the next wave of breakthrough medicines. Baylink's approach leverages novel linkers combined with innovative payloads to build highly differentiated products for treatment of cancer. Baylink's linkers overcome key challenges with antibody drug conjugates: tumor resistance, lack of payload diversity, and narrow therapeutic window. Using innovative linker designs, Baylink scientists created a panel of linkers enabling delivery of challenging drug payloads. Drugs hydrophobic in nature are problematic for delivery using traditional ADC linker technology. Baylink's linker technology allows conjugation of hydrophobic payloads with high DAR. The linker technology reduces non-tumor-antigen-specific uptake into healthy tissues reducing potential for adverse events. Resulting ADCs have potential for better efficacy and safety. The platform enables delivery of multiple payloads, so called dual payload ADCs. Visit [www.baylinkbio.com](http://www.baylinkbio.com)



Carrigent is advancing next-generation delivery for cell and gene therapy. Our flagship platform, CARGO, is a novel non-viral system designed to deliver large genetic or protein payloads directly to target cells in vivo—with high specificity, reduced toxicity, and significantly lower dose requirements. By overcoming the size and immunogenicity limitations of current viral systems, CARGO has the potential to unlock previously inaccessible therapeutic strategies and reduce the cost of gene therapy development. Alongside CARGO, we are also innovating in viral vector production, developing tools that improve payload expression, reduce manufacturing costs, and expand vector capacity. Our team supports partners through contract research and preclinical process development across viral systems including LVV, RVV, AAV, AdV, and oncolytic viruses. Carrigent is actively seeking collaborators to explore the potential of CARGO and accelerate the next wave of gene therapy innovation.



Inomagen Therapeutics, Inc. is a private, preclinical stage biotechnology company pioneering a gene therapy to improve the treatment of atrial fibrillation. Inomagen has intellectual property and proof of concept data for both the gene and the gene delivery system. Inomagen has a strong and experienced team of industry veterans and key opinion leading cardiovascular physicians to engage in management and advisory roles, including those with extensive domain experience in gene therapy, cardiology, AF therapeutics, medical device, clinical studies, and venture capital. The market size for Inomagen's gene therapy products is \$10.2B.

# 11:00 AM | SESSION 10 - MEDICAL DEVICES & DIAGNOSTICS



AirSeal CV is developing PADGuard™, a first-in-class blood test designed to diagnose Peripheral Arterial Disease (PAD). PAD is the leading cause of limb disability and amputation, yet many patients remain undiagnosed, missing the opportunity to intervene with drug, behavior modification, and interventional procedures to prevent disease progression. Conventional blood tests such as LDL (bad cholesterol) are not diagnostic for PAD. Currently, the gold standard for PAD diagnosis is the ankle-brachial index (ABI), a procedure that is often inaccessible, not accurate, and not reimbursed by Medicare for asymptomatic patients. PADGuard (Circulating Fatty Acid Synthase) unlike LDL is diagnostic for PAD - predictive for amputation risk providing actionable information to inform treatment decisions with proven outcomes benefits meeting the needs for scalability and cost-effectiveness that will transform PAD management. AirSeal CV has a vetted operational plan with a portion of the equity round committed and diligence in process with multiple investors.



Chemeleon has created a novel diagnostic platform, combining silicon photonics with high-affinity molecular receptors to create an instrument-free, point-of-care diagnostic that provides a semi-quantitative colorimetric readout in minutes with lab-grade precision. For life-threatening conditions where every minute counts, like acute myocardial infarction (AMI), our assay can detect and quantify concentrations of protein biomarkers, like troponin, to diagnose AMI in under two minutes with high precision. This rapid, cost-effective, and highly accurate test will emergency department staff to quickly diagnose AMI and initiate critical interventions, saving lives and drastically reducing healthcare costs. We're initially targeting the \$5.9 billion high-sensitivity cardiac troponin assay market and expanding to other indications in the \$12.5 billion rapid acute care diagnostic market with broader applications in the \$62.3 billion global point-of-care diagnostic market. We secured significant seed funding, including over \$2 million in NSF and NIH Phase I and II SBIR grants.



Covanos, Inc. is an advanced medical technology company revolutionizing coronary artery disease (CAD) diagnosis with C-Heart™, its AI-enabling, point-of-care software platform. C-Heart integrates coronary CT angiography with proprietary physics-based computational fluid dynamics to deliver rapid, accurate assessments of blood flow impairment—guiding decisions on stenting in patients with suspected CAD - a \$10B U.S. total addressable market. C-Heart is the first non-invasive solution that reports out instantaneous wave free ratio (iFR) and unlike cloud-based competitors, C-Heart runs securely on local hospital systems, ensuring data privacy, faster results, and seamless clinical workflow integration. Its SaaS-based model improves reimbursement and health economics while reducing unnecessary invasive procedures. Covanos is raising \$4M in a convertible note to advance C-Heart investors a scalable, high-margin solution with near-term commercial impact and long-term potential for predictive AI-driven cardiovascular care.



Echopoint Medical is at the forefront of advancing diagnostic cardiology with its innovative iKOr system, designed to provide complete coronary physiology data for improved cardiac treatment decisions. As a company founded at University College London and structured as a Delaware C-Corp, Echopoint has made significant strides in developing a unique fiber-optic, laser-based microcatheter system that offers superior accuracy in coronary flow measurement. With a successful first-in-human trial in London, secured reimbursement codes for coronary flow reserve (CFR) measurement, and a clearly defined FDA 510(k) regulatory pathway with clearance expected in Q1 2026, Echopoint is now poised to expand its footprint into the U.S. market. The commercialization of the iKOr system in the United States represents a significant opportunity, given the unmet clinical need for better diagnostic tools for ischemia with non-obstructive coronary artery disease (INOCA) and related conditions.

## 1:00 PM | SESSION 11 - MEDICAL DEVICES

Buckle Therapeutics has developed a patented device for fast, pain-free delivery of drugs directly to the bloodstream via the mucosal lining of the inner cheek. Our applicator, coupled with an ethanol-based adhesive solution, protects the drug from degradation by saliva, while it moves rapidly across the buccal surface, avoiding first-pass metabolism in the gut and liver. Our first commercial product is an affordable, easier-to-use naloxone for reversing opioid poisoning, a billion-dollar market, now dominated by the \$500M Narcan® franchise. Our next product is buccal epinephrine, addressing the \$2.5B anaphylaxis market, dominated by the EpiPen® auto-injector. This market is likely to expand significantly in response to the 2024 introduction of an intra-nasal spray. Additional indications address anxiety, migraine, seizure disorders and post-surgical pain. We are raising our Series A round to secure regulatory approval and for the initial launch of naloxone in 2027, as well as advancing epinephrine into the clinic.



Ditch Labs is a clinical-stage healthtech company developing the DitchPen®, the world's first medically regulated inhaled nicotine replacement therapy (NRT). Designed to precisely mimic the nicotine delivery of a cigarette, DitchPen® delivers controlled, adjustable doses to help smokers gradually reduce dependence. Paired with the DitchApp, a digital therapeutic companion that tracks progress and offers behavioral support, the system personalizes each user's cessation journey. Available by prescription or over-the-counter depending on the market, Ditch's approach addresses the pharmacological and psychological dimensions of addiction. Backed by top-tier investors and scientific advisors, Ditch Labs is preparing to launch in the UK, where smoking remains the leading cause of preventable death.



Swan NeuroTech is a pre-clinical medical device startup founded in 2019 by Kacey Marra, PhD as a spin out from the University of Pittsburgh. SNT is the culmination of 20 years of scientific research in nerve regeneration and advanced biomaterials by Dr. Marra in the McGowan Institute. The DOD's support of Dr. Marra's nerve regeneration research with \$5MM in non-dilutive grant funding led to the formation of SNT. SNT's mission is to develop novel regenerative therapies that transform the care of patients with peripheral nerve injury (PNI) a \$1.7B market. Patient outcomes following PNI are extremely poor - only 10% of patients fully recover from a severe PNI, and up to 40% of patients are unable to return to work within a year of their injury. SNT's first product, NeuroMax, is able to regenerate severe (large gap) PNI's better than current standard of care in non-human primates.



Hospital acquired infections, and specifically infections surrounding implantable medical devices (IMDs), continue to be a massive healthcare and societal problem, costing billions of dollars globally and causing different degrees of suffering, even leading to death in many cases. The problem is compounded by microbial resistance to antibiotics, making these infections extremely difficult to treat. Novaurum is developing coating technology for implants using Atomic Layer Deposition (ALD) to create an antimicrobial nano surface that inhibits the formation of biofilm and the colonization of all strains of microbes, including antibiotic-resistant strains, and that is completely biocompatible.



## 2:00 PM | SESSION 12 - THERAPEUTICS



Amporin Pharmaceuticals AG is an emerging Swiss biotech startup founded in April 2024 by a small team of ex-Pharma drug discovery and development leaders. The company is developing a breakthrough new class of small molecule “amyloid pore” inhibitors that can uniquely protect and repair cell membranes as the first potential acute oral disease-modifying treatments to stop and reverse over 50 deadly degenerative diseases associated with protein misfolding and aggregation, including Alzheimer’s, Parkinson’s, Huntington’s, ALS, type II diabetes, and many rare diseases. The company is seeking to raise USD 10-12 million seed funding, with a vision to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease and ALS.



QPMind is redefining biotech. As the first company to fuse cutting-edge AI with Quantitative Systems Pharmacology (QSP), QPMind is building an intelligent platform to revolutionize drug discovery—starting with central nervous system (CNS) diseases. Founded in 2023 by biotech veterans with deep expertise in AI, QSP, and drug development, QPMind is launching with two Alzheimer’s drug candidates and several orphan tauopathy indications, in collaboration with Sanford Burnham. Discovery-stage programs are also underway in Parkinson’s, schizophrenia, and an especially novel program in chronic pain. At the heart of QPMind is a growing library of AI-enhanced QSP models—what the team calls a “super mind” for drug discovery—designed to reduce clinical trial costs and increase success rates by up to 5x. QPMind operates as a holding company, with each drug housed in its own LLC for focused investment and partnership opportunities, all powered by a shared, AI-driven discovery platform.



Serenatis Bio is a start-up biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness with huge unmet need and commercial opportunity. Each drug has a different mechanism of action - targeting glutamate and dopamine receptors - using precision medicine to identify which OCD patients will respond to which drug. Our first drug will be ready for clinical trials next year while our second and third ones will enter GLP tox studies.



Stream Biomedical, Inc., a privately held clinical-stage biopharmaceutical company, is dedicated to the development of first-in-class targeted therapeutics for the treatment of acute and chronic traumatic and neurodegenerative diseases. rhPDV-LG3, our lead molecule, is a potentially transformative 21kD recombinant protein that, like endogenous LG3, restores homeostasis to multiple tissues within the neurovascular unit. Multiple beneficial effects are observed following a single dose in animal models for acute ischemic stroke, traumatic brain injury, and repeat blast injury. Similar findings using chronic dosing were observed in an Alzheimer’s disease model. Like endogenous LG3, upregulated only following tissue injury, rhPDV-LG3 crosses the BBB, homes to the site of injury by binding to upregulated integrin receptors, and demonstrates rapid, profound, and durable cerebroprotective effects. Toxicology studies show no safety concerns. A phase 1 study of rhPDV-LG3 in NHVs is underway. Phase 2 clinical trials in acute ischemic stroke and TBI are planned for 1H’26.

## 3:00 PM | SESSION 13 - THERAPEUTICS



DuPage Medical Technology, Inc. (DMT, Inc) is a start-up biotechnology company located in Chicago. We currently focus on 1 novel drug and 1 novel drug delivery nanotechnology: (1) The one drug: A new-concept dual anti-thrombotic and anti-inflammatory drug that does not exacerbate bleeding and does not exacerbate bacterial infection. Preclinical pharmacological studies demonstrate that this drug is effective in treating (i) ischemia-reperfusion injury (following heart attack, cardiac arrest, and organ transplant), (ii) sepsis and pneumonia, (iii) certain autoimmune diseases. (2) The one drug delivery nanotechnology: high-loading peptide nanoparticle (HLPN) technology for efficiently delivering peptides into cell in vivo for therapeutic use. The company licenses inventions from the University of Illinois at Chicago (published in high quality journals e.g. Science, Nature, Science Translational Medicine and Nature Communications). Supported by Phase II SBIR grants from NHLBI. We seek investment and /or partnership to facilitate regulatory approval and clinical trials.



Rhythm Biotherapeutics Inc. is a clinical-stage biotech company pioneering the use of heart-derived extracellular vesicles (EVs) to prevent and treat atrial fibrillation (AF). Our proprietary, naturally enriched EVs target key inflammatory and fibrotic pathways driving AF, offering a disease-modifying approach without the toxicity risks of current antiarrhythmic drugs. Supported by strong preclinical data across rodent and large-animal models, our lead candidate is manufactured in a GMP facility and advancing toward a Phase 1 clinical trial. Rhythm's platform leverages a patented process to produce EVs with high potency, scalability, and safety. With early validation in human tissues and cross-species efficacy, our technology represents a first-in-class therapeutic for postoperative and chronic AF. Headquartered at the University of Ottawa Heart Institute, Rhythm Biotherapeutics is backed by a seasoned team with expertise in cardiovascular research, cell therapy, and regulatory development. We are seeking strategic partners and investors to accelerate clinical translation and commercial readiness.



AmacaThera is developing a pipeline of long-acting injectable products. With applications from oncology to pain and from anti-infectives to disease prevention. AmacaThera's lead asset is Phase 2 ready with preclinical stage pipeline assets. AmacaThera has successfully secured two top 10 pharma deals to evaluate and co-develop assets. AmacaThera is actively raising to advance the clinical development of the lead asset and to secure additional partnerships. AmacaThera is highly capital efficient and has achieved all of this success with only \$12M. The aim of the current round to to generate sufficient data with the lead asset to secure a partner. This round will also provide optionality with additional partnerships.

## 4:00 PM | SESSION 14 - THERAPEUTICS



Eleva is a clinical-stage biopharma company that strives to bring novel therapies to patients in need. Partnerships are at the heart of our strategy and our unique moss-based platform and capabilities can unlock a range of 1st- and best-in-class biologics. We are currently advancing two proprietary clinical programs, which have the potential to change the life of patients affected from complement-related disorders and Fabry disease. Moreover, Eleva is currently looking for additional investors and partners to accelerate the development of these clinical assets towards market approval. Moreover, Eleva scouts for promising novel compounds that will benefit from Eleva's technology and expertise. We are open to alliances to initiate partnered discovery and development projects.



Our lead product, MLB-001, is a first-in-class, combination drug designed to deliver powerful, life-changing pain relief using significantly lower morphine doses. MLB-001 achieves equal or superior analgesic effects compared to conventional morphine, while minimizing common side effects and reducing the development of drug tolerance. Importantly, MLB-001 is specifically engineered to lower the risk of addiction, a critical advancement given the ongoing opioid crisis. MindLab is committed to redefining pain care by introducing safer, more effective treatments that address unmet medical needs and promote better quality of life for patients worldwide."



Mirscience is developing oligonucleotide-based therapies to restore function in muscle and metabolic diseases. Our proprietary platform, GOAT, targets previously untapped non-coding RNAs—such as miRNAs, lncRNAs, and circRNAs—that play key roles in regulating disease pathways. By engineering highly specific and programmable molecules, we unlock druggable opportunities where traditional approaches have failed. Our lead program, MT-29, increased muscle mass by 21% and strength by 12% in aged mice, while also boosting muscle mass and strength by 17% in healthy animals. These results position MT-29 as a promising therapeutic candidate for muscle-wasting diseases.

# 9:00 AM - 4:50 PM | INVESTOR PANEL & WORKSHOPS

Location: St. George C

## Presenters

9:00 - 9:50 AM



### IT ALL STARTS WITH YOUR STORY

**Greg Mannix**, VP of International Business Development, Life Science Nation  
**Max Braht**, Director of Business Development, Life Science Nation

10:00 - 10:50 AM

### TALES FROM THE ROAD


*Biotech and MedTech Innovators on their Fundraising Journey*

**Greg Mannix**, VP of International Business Development, Life Science Nation   
**Richard Austin**, Co-Founder and CEO, Reglagene, Inc.  
**Gonzalo Fernández-Miranda**, CEO, CureAge Therapeutics  
**Christoph Meinert**, CEO, Gelomics  
**Prem Prensirut**, President/CEO, Mirimus Inc.

11:00 - 11:50 AM

### CROSS-BORDER VENTURE BUILDING STRATEGIES

*How Service-for-Equity & Global Structuring Can Transform Early-Stage Therapeutics Partnerships*

**Sougato Das**, President and Chief Operating Officer, Life Science Nation   
**Dennis Ford**, Founder & CEO, Life Science Nation; Creator of RESI Conference Series  
**Simon Hua**, Chairman, BioMetas  
**Rick Berenson**, Executive Committee Member, Mass Medical Angels (MA2), Managing Director of Venzme Catalyst

1:00 - 1:50 PM

### FAMILY OFFICES PANEL PANEL

*Perspectives on Early-Stage Investments*

**Andrew Merken**, Shareholder, Polsinelli PC   
**John Abeles**, General Partner, Northlea Partners  
**Ethan Berg**, Managing Partner, G4 Investments, LLC  
**Michael Langer**, Founder & Managing Partner, T.Rx Capital  
**John Leader**, Partner, Green Park & Golf Ventures  
**John Parker**, Founder and Managing Director, Springhood Ventures

2:00 - 2:50 PM



### TERM SHEETS

**Jeremy Arak**, Shareholder, Venture Capital and Emerging Growth Practice, Polsinelli  
**Prithvi Tanwar**, Office Managing Partner, Boston and Shareholder, Venture Capital and Emerging Growth Practice, Polsinelli

3:00 - 3:50 PM



### GLOBAL PARTNERING CAMPAIGN INVESTOR LANDSCAPE, GTL AND CRM/GPC

**Karen Deyo**, VP of Product, Israel Business Development, Life Science Nation  
**Joey Wong**, Director of Investor Research, Mainland China, Taiwan & Hong Kong BD, Life Science Nation

4:00 - 4:50 PM



### COMPANY VALUATION FOR FUNDRAISING

**Patrik Frei**, Founder & CEO, Venture Valuation AG, Switzerland

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company's unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.

**Greg Mannix**, VP of International Business Development, Life Science Nation



Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

**Max Braht**, Director of Business Development, Life Science Nation



At Life Science Nation (LSN), Max leads the Global Business Development team and directly oversees the U.S. East Coast region, where he is based. He is responsible for assisting early-stage companies across the life sciences — including therapeutics, devices, diagnostics, and digital health — in expanding beyond their local regions and connecting with global investors through participation in LSN's Redefining Early Stage Investments (RESI) conference and the use of LSN's curated Investor Platform. Max holds an MBA from Oklahoma State University, as well as an MiM and an MSc in Artificial Intelligence & Digital Technology Management from the Burgundy School of Business in Lyon, France.

## SHAPING THE FUTURE OF ENERGY-DRIVEN TECHNOLOGIES.

Collaborate with Tecan to accelerate breakthroughs in energy-based therapies and tissue therapeutics.



Improve power efficiency



Balance competing parameters



Working prototypes in months, not years



Learn more about Tecan technology development for MedTech.



The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more:

- What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
- How did entrepreneurs identify investors that fit their technology?
- What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

### **Greg Mannix, VP of International Business Development, Life Science Nation**



Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

### **Richard Austin, Co-Founder and CEO, Reglagene, Inc.**



Richard is a seasoned biotech entrepreneur and CEO of Reglagene, a company pioneering therapies for brain diseases. With over 30 years in the pharmaceutical industry, he brings deep expertise in drug development, R&D operations, and business strategy. Richard has led both startups and multinational firms, consistently driving innovation and growth. At Reglagene, he guides a dedicated team advancing treatments for brain cancers and actively seeks partnerships to accelerate impact. He's also an angel investor with Desert Angels and a member of the Southern Arizona Leadership Council, supporting regional biotech innovation. Richard's vision, leadership, and commitment to transforming healthcare make him a key force in advancing novel brain disease therapies.

### **Gonzalo Fernández-Miranda, CEO, CureAge Therapeutics**



Gonzalo is an accomplished expert in company creation and entrepreneurship, having co-founded Ninevah and Nanobots Therapeutics. With a successful exit and experience in executive roles, he brings extensive expertise in rare diseases, RNA therapeutics and gene therapy.

### **Christoph Meinert, CEO, Gelomics**



Dr. Christoph Meinert is the Co-Founder and CEO of Gelomics, a biotech company transforming drug development with AI-powered 3D tissue culture technologies. Since earning his PhD in 2017, he has published over 50 papers with 3,200+ citations and an h-index of 25. He has received 18 awards, including the QUT Outstanding PhD Thesis Award and the Siganto Foundation Medal. Since becoming CEO in 2023, Dr. Meinert has raised over \$12M, launched 17 products, and expanded Gelomics to 23 global markets. A 2024 KPMG Tech Innovator and graduate of the Australian Institute of Company Directors, he leads Gelomics in replacing animal testing with scalable, human-relevant solutions to advance global drug discovery.

### **Prem Prensirut, President/CEO, Mirimus Inc.**



Dr. Prem Prensirut is President and CEO of Mirimus, a biotech company advancing RNAi and CRISPR-based animal models for preclinical drug evaluation. A pioneer in transgenic RNAi mouse technology, she co-developed a high-throughput platform for rapid gene target validation and toxicity testing. She also introduced a novel method for generating fast-track cancer-prone chimeric GEMMs. Dr. Prensirut earned her MD/PhD from SUNY Stony Brook and Cold Spring Harbor Laboratory, where she trained under Dr. Scott Lowe, focusing on lung cancer and tumor maintenance using RNAi. She holds a B.A. in Molecular Cell Biology and Biochemistry from UC Berkeley and previously conducted research at Mount Sinai on G-protein signaling pathways related to addiction and neuronal development.

## 11:00 AM | CROSS-BORDER VENTURE BUILDING STRATEGIES: HOW SERVICE-FOR-EQUITY & GLOBAL STRUCTURING CAN TRANSFORM EARLY-STAGE THERAPEUTICS PARTNERSHIPS

Join BioMetas, Life Science Nation (LSN), and MA2 leaders as they discuss a new model for accelerating early-stage therapeutics. This panel explores how a cross-border accelerator alliance reshapes startup success through service-for-equity development, global commercialization support, and jurisdictional structuring, including reverse Delaware flips to Singapore. Learn how this integrated approach helps startups overcome capital gaps, generate high-value data, and access global markets and investors.

### **Sougato Das**, President and Chief Operating Officer, Life Science Nation



Sougato Das is the president of Life Science Nation, provider of the RESI conference series. Previously he was the managing director of partnering at BIO, where he created/led the partnering system, logistics, customer service, JPM event and BD models BIO used from 2015 to the start of 2025. Later, as general manager of events at Inpart.io, Sougato ran partnering for a multitude of partnering events including LSX World Congress, Advanced Therapies Week, BioSpain and others. He has extensive knowledge on the 'behind the scenes' processes that lead to securing meetings with desirable partners and moving those meetings into deals, as well as the rich ecosystems that have developed around JPM and Convention. Prior to BIO, Sougato consulted for a variety of large life sci companies including including J&J, GSK, Merck, Sanofi, Siemens Medical, IQVIA and Clarivate.

### **Dennis Ford**, Founder and CEO, Creator of RESI Conference, Architect LSN Labs



Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. Dennis has spent a decade in the early-stage life science arena creating a partnering platform that matches next-generation drugs, devices, diagnostics, and digital health products with investor and licensing partners. Dennis has developed an active network of global investors ranging from Family Offices, Private Equity, Venture Capital, Foundations, and Endowments to large Corporate and Pharmaceutical firms interested in high-growth early-stage technologies. Dennis has also pioneered a unique global partnering event called the Redefining Early-Stage Investments Conference Series that matches investors and licensing partners with startup firms based on stage of development and product.

Dennis is the author of *The Peddler's Prerogative* and *The Fund Manager's Marketing Manifesto*, two well-received sales and marketing books. His latest book is *The Life Science Executive's Fundraising Manifesto* which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO which is now offered to help launch and fund startups into the global life science arena.

### **Simon Hua**, Chairman, BioMetas



Simon Hua is the Chairman of BioMetas Group, a leading CRO based in Shanghai, and the Chairman of China Finance Strategies Investment Holdings, a Hong Kong-based investment group. He was previously a Co-Founder of Viva Biotech, a globally recognized CRO. With a strong background in both the life sciences and financial sectors, Simon has extensive experience in investment strategy, business development, and corporate leadership. He holds an MBA in Finance from the International University of Japan.

### **Rick Berenson**, Executive Committee Member, Mass Medical Angels (MA2), Managing Director of Venzme Catalyst



Rick Berenson will present a practical approach for how family offices can assess early-stage biotech without building a whole internal diligence team. As a 15-year leader at Mass Medical Angels (MA2)—a Boston-based life science group made up entirely of industry veterans—Rick has helped refine a model that quantifies risk and potential return by leveraging the "wisdom of an expert crowd." He'll explain how MA2 has used targeted micro-investments to derisk promising projects and turn them into investable biotech companies and how family offices can take advantage of this model to build a capital-efficient, scalable biotech investment pipeline.

# 1:00 PM | FAMILY OFFICES PANEL

## Perspectives on Early-Stage Investments

This panel focuses on understanding how family offices view direct investments in early-stage healthcare opportunities (seed – series A) and how they differ from and compare to VCs. Topics may include:

- Primary differences between institutional VCs and family office investors
- How family offices source investments / how to get on their radar
- Trends in the early-stage healthcare investment space

The primary goal of this panel is to help entrepreneurs understand how family offices view early-stage investments in the healthcare space and best practices for approaching, pitching, and working with these groups as well as debunking some common misconceptions about family offices.

### **Andrew Merken**, Shareholder, Polsinelli PC



Andrew Merken is a nationally recognized corporate and transactional lawyer advising early to growth-stage companies across the full business lifecycle, from formation to funding, M&A, and IPO. He provides strategic counsel and works closely with subject matter experts in FDA, IP, employment, tax, and cross-border matters. Andy also represents VC funds, angel investors, family offices, and foundations in investments and collaborations, as well as investment banks in public and private offerings. His clients span life sciences, including biotech, pharma, medtech, and digital health, as well as high-tech sectors such as consulting, real estate, and food services. Andy is known for guiding companies through complex deals and delivering practical, business-oriented legal advice.

### **John Abeles**, General Partner, Northlea Partners



Dr. John H. Abeles, BSc(Hons), MBChB, is a physician, pharmacologist, and seasoned biomedical investor. After earning medical and pharmacology degrees from the University of Birmingham (UK), he practiced medicine in London and Connecticut before holding senior roles at Sterling Drug, Pfizer, and USV. In 1975, he became Wall Street's first full-time MD securities analyst with Kidder Peabody. He later founded MedVest Group and Northlea Partners, focusing on biomedical venture capital. Dr. Abeles has backed numerous early-stage biotech companies, many of which went public or were acquired. He has served on advisory boards at UC Berkeley, Stanford, and the University of Kansas, and supports multiple healthcare and arts nonprofits globally.

### **Ethan Berg**, Managing Partner, G4 Investments, LLC



Ethan Berg is the founder and chief investment officer of G4 Partnership, an investment partnership dedicated to the implementation of the investment discipline of Ben Graham, Warren Buffett and Seth Klarman. Prior to founding G4 Partnership in 2000, Ethan was a management consultant at Monitor Group for six years, including two years of working directly for Michael Porter.

### **Michael Langer**, Founder & Managing Partner, T.Rx Capital



Michael is Head of Search, Evaluation and In-licensing for all new technology and products at Pear Therapeutics. Michael is the founding partner at Old Silver VC. He also invests directly into Seed and/or Healthcare/Biotech focused venture capital funds as a Limited Partner. He is a mentor and Judge at MassChallenge Healthtech and a mentor at MassConnectDH. He co-founded the Young Coder's Society. He is a World Economic Forum Global Shaper, serves on The Discoverers Committee at the Museum of Science, the Visionaries Circle at The Possible Project and is the Senior Advisor of Special Projects at the Galenus Foundation. Prior to Pear and Old Silver VC, Michael spent time at: Akili Interactive Labs, Udacity, Modern Meadow, Polaris Partners, The Harvard Experiment Fund and Boston Seed Capital. Michael has a BA from Lehigh University.

### **John Leader**, Partner, Green Park & Golf Ventures



John is a Partner in GPG Ventures' Houston office having been with the firm since May of 2019. John oversees the deal pipeline and evaluation of potential investment opportunities as well as managing the post-investment activities related to portfolio company and investor relations. He also serves as a board observer for the Houston office's medical device and services investments. John has extensive venture and entrepreneurial experience in the early-stage healthcare, commercial real estate, and software industries among others. Since January 2017, he has managed over 75 venture transactions comprising more than \$100 million in early-stage healthcare companies. John is a native Houstonian and holds a B.S.B.A. from Georgetown University's McDonough School of Business. He currently splits his time between Houston and Boston where his fiancée completes a medical fellowship at Mass General Hospital.


### **John Parker**, Founder and Managing Director, Springhood Ventures



John founded Springhood Ventures to provide critical early support to companies developing important healthcare solutions for children. In this role, he also established and manages the program-related investment (PRI) initiative of the Charles H. Hood Foundation, a Boston-based private foundation that supports pediatric research, where he also serves as a trustee. Springhood invests on a mission-first basis in seed-stage companies developing important pediatric medical solutions. He is also an observer on the boards of Prapela, Inc., Aldatu Biosciences, Breegi Scientific, and Noninvasix, Inc. Previously, John spent 25 years in the alternative investment industry, including senior roles in venture capital, private equity, and hedge funds. John has a BA from Dartmouth College and an MBA from Dartmouth's Tuck School of Business.


## 2:00 PM | POLSINELLI WORKSHOP TERM SHEETS

**Jeremy Arak**, Shareholder, Venture Capital and Emerging Growth Practice, Polsinelli



Jeremy Arak provides timely, pragmatic advice to emerging growth companies and investors across a wide array of industries. Jeremy acts as an advisor and outside general counsel, advising entrepreneurs, startups and high-growth companies throughout their life cycles. Focusing on gaining a deep understanding of client business, Jeremy helps with day-to-day business needs, venture capital financings, commercial relationships, and corporate governance matters. Jeremy focuses on simple, solutions-oriented approaches to challenges in order to provide efficient, comprehensive counsel, bringing clarity to complex issues to help clients achieve their business objectives.

**Prithvi Tanwar**, Office Managing Partner, Boston and Shareholder, Venture Capital and Emerging Growth Practice, Polsinelli



Prithvi Tanwar serves as general corporate counsel to early and growth stage technology companies building innovative products and services that are changing business processes and the way individuals use and interact with technology on a daily basis. Over the past decade he's worked with hundreds of entrepreneurs to advise them and their companies through all stages of growth and serve as the company's tactical and strategic advisor on legal and business issues that arise in day-to-day operations. Prithvi works with clients who are distributed throughout the United States and overseas. Prithvi has advised scores of foreign origin companies in connection with their establishment of a legal presence in the US both to raise venture capital and access the US commercial markets while still retaining their foreign operations. Prior to his career in law, Prithvi was a technology management consultant, working on large-scale technology implementations and business process changes. He also co-founded his own software-based start-up while in college.

## 3:00 PM | GLOBAL PARTNERING CAMPAIGN INVESTOR LANDSCAPE GTL AND CRM/GPC

Once you are ready to embark on your fundraising campaign, how do you know whom to target? What investors are a best fit for you, how do different investors invest and partner, and how do you get in touch with them? Identifying investors, learning about the differences between investor types, accessing a database to provide you with key information to filter your best fit investors, and finally, using a CRM to manage your fundraiser are critical to an efficient and successful fundraise.

**Karen Deyo**, VP of Product, Israel Business Development, Life Science Nation



Karen Deyo is the VP of Product at Life Science Nation, responsible for new product development and LSN's educational content. In addition to her role as VP of Product, she is actively involved in Israel BD, utilizing her professional and personal connections to connect LSN to the Israeli life sciences startup community. She started out at LSN as part of the investor research team, speaking to investors and learning their investment mandates. Karen utilizes her experience speaking with investors as well as her scientific background to help startups translate their science and prepare for their global partnering campaigns. Karen has a Masters of Engineering in Biomedical Engineering as well as a Certificate in Graduate Business Study from Worcester Polytechnic Institute and a Bachelor of Science degree in Engineering with a concentration in Bioengineering from Olin College of Engineering.

**Joey Wong**, Director of Investor Research, Mainland China, Taiwan & Hong Kong BD, Life Science Nation



Joey Wong is Director of Investor Research at Life Science Nation (LSN), where she builds and manages a strong network of early-stage investors, facilitating meaningful connections between startups and investors or strategic partners. She contributes to the LSN Investor Database Platform and helps develop programming for the RESI (Redefining Early Stage Investment) conference series. Joey has experience in business development across Mainland China, Hong Kong, and Taiwan, with a focus on the life science and healthcare sectors. She works closely with key players in the regional ecosystem and supports cross-border collaborations. Before moving into investor research and business development, she was involved in research at a neuropsychology laboratory.

# 4:00 PM | VENTURE VALUATION WORKSHOP COMPANY VALUATION FOR FUNDRAISING

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don'ts when speaking with investors and look at how to value a life science company with no revenues.

**Patrik Frei**, Founder & CEO, Venture Valuation AG, Switzerland



Dr. Patrik Frei is the founder and CEO of Venture Valuation AG, a company he established in 1999 to provide independent valuation services for high-growth industries. His first client was Novartis Venture Fund, and he has since conducted over 450 valuations for investors, biotech, pharma, and medtech companies. Patrik earned his degree from the University of St. Gallen and completed his PhD at EPFL Lausanne, focusing on the assessment and valuation of high-growth companies. He has served on the boards of Ineo, Aventron AG, and Ophthalmopharma, where he successfully out-licensed a portfolio of products. His articles have been published in journals such as "Nature Biotechnology" and "Chimia," and he has authored business publications. Dr. Frei also lectures on valuation at institutions like Seoul National University, EPFL Lausanne, and the University of St. Gallen, offering workshops globally.



## MEDIA PARTNERS



Want to become a RESI Media Partner? Contact us at [Marketing@lifesciencenation.com](mailto:Marketing@lifesciencenation.com)